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ABSTRACT OF THE DISSERTATION
APTAMER SENSORS FOR DRUGS OF ABUSE AND MEDICAL BIOMARKERS:
DESIGN, ENGINEERING, AND APPLICATION IN COMPLEX SAMPLES
by
Daniel Roncancio
Florida International University, 2018
Miami, Florida
Professor Yi Xiao, Major Professor
Aptamers are short oligonucleotide sequences (DNA or RNA) capable of high
affinity and specific binding to a molecule or a family of molecules. Aptamers are
lower in cost and exhibit higher reproducibility when compared to antibodies and
thus are well-suited for recognition and detection of small molecular targets such
as drugs of abuse and small medical biomarkers. While aptamers have been
extensively utilized for development of small molecule sensors, several limitations
prevent measurements of complex or real-world samples. This dissertation
describes methods, technologies, and assays that were developed with the goal
of producing and/or improving aptamer-based sensors for target detection in
complex samples. Aptamer engineering is detailed as an important facet of
maximizing aptamer-sensor sensitivity and specificity, along with adaptation to
various read-out mechanisms for improved selectivity. In chapter 3, an aptamer

vi

sensor for cocaine is developed based on binding between the fluorophore
ATMND to the cocaine aptamer which results in quenching (i.e., ‘turn-off’) of the
fluorescence of ATMND. Cocaine binding results in displacement of the ATMND
and recovery of the fluorescence signal. Detection of cocaine is demonstrated with
an engineered cocaine aptamer with higher affinity for cocaine, permitting over a
50-fold increase in sensitivity over other aptamer-based sensors. The method can
be used in dilute biological fluids (e.g., saliva) with a single step reaction (seconds)
and robust signal output. In chapter 4, a new adenosine specific aptamer is
identified through rational engineering of a previously reported ATP-binding
aptamer. The new adenosine aptamer is utilized to develop an electrochemical
sensor for detection of adenosine in undiluted serum. The method displays 40-fold
higher sensitivity in undiluted serum measurements over previously reported
aptamer-based sensors for adenosine but also demonstrates specificity for
adenosine over ATP, ADP and AMP that has not been previously reported. In
chapter 5, a nuclease-guided truncation method is developed to yield optimal
structure-switching

aptamer

methylenedioxypyrovalerone

sequences
(MDPV)

and

for

the

medical

emergent
biomarkers

illicit
ATP

drug
and

deoxycorticosterone 21-glucoside (DOG). The method intelligently removes
unessential nucleotides, producing truncated aptamer sequences with structureswitching functionality. This technique will be immediately useful for simple and
low-cost development of aptamer-based electrochemical sensors.
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CHAPTER 1
Introduction
1.1

Overview

The detection of small molecules is integral to various aspects of modern living
including medical diagnostics, environmental monitoring, and law enforcement.
Accurate identification of a single molecule in a heterogeneous mixture requires
high specificity to discriminate between competing molecules and high sensitivity
to correctly measure the mean concentration of even trace analyte amounts.
Instrumental analysis provides the highest discriminatory level (i.e., high
specificity) and high sensitivity, thus it is generally accepted to be the gold standard
of chemical analysis. However, these methods still require expensive and
cumbersome machines, expert technicians, complex procedures, and long turnaround times for sample analysis. Biosensors are devices which combine highly
specific and high-affinity molecular recognition of an analyte with simple and lowcost signal transduction. Biosensors have demonstrated similar analytical
capabilities as expensive and complex analytical instruments but with exceptional
convenience, instantaneous results, and lower cost. Today, a person can walk to
a drugstore and purchase bio-sensing devices, aimed at detecting vastly different
molecules including exogenous compounds such as drugs of abuse and
endogenous compounds like medical biomarkers. Within minutes, an accurate
representation of the analyte can be obtained in complex biological fluids without
requiring any specialized training. The analyte concentration can be used to
diagnose disease, monitor health status or drug use.
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Biosensors are designed by combination of a recognition element and a
transduction element. The recognition element provides specific binding and highaffinity interactions with the analyte against other molecules present in a sample.
The transduction element converts the binding interaction between the recognition
element and the analyte into a measurable signal that can be interpreted visually
or instrumentally. Recognition elements include biological molecules such as
antibodies,

enzymes

and

more

recently,

aptamers

(i.e.,

DNA/RNA

oligonucleotides). Antibody-based biorecognition is still widespread because of the
excellent analytical characteristics of antibodies (high specificity and sensitivity)
and nearly sixty years of research and development.1 More than two million
antibodies are commercially available from hundreds of companies.2 Several
examples of antibody-based sensors are commonly known to the general
population including: pregnancy tests, ovulation kits, and drug screening
immunoassays. Unfortunately, the generation of antibodies requires animal
immunization which is not universally applicable for every molecule, such as in the
case of immunosuppressive molecules and toxins.3,4 Additionally, antibody
reliability and specificity is highly source-dependent with susceptibility to batch-tobatch variation and non-specific binding to off-target molecules. Indeed, landmark
publications have been retracted because of difficulty in reproducing scientific
findings obtained with antibodies. Authors of such publications have advised
caution and recommended careful validation of individual antibody assays.5,6 In
the context of small molecule detection, antibody-based sensors require
specialized molecular components to transduce the binding interaction with the
2

analyte into a measurable signal. For example, a chemically labeled target can be
added to the sample as a signal marker by competing with the free target for the
antibody binding site.7 Only the labeled-target can report interactions with the
antibody and any disturbance of the interaction is a representative signal that free
target is present. Similarly, an enzyme-labeled target can be utilized to compete
with the free target. The enzyme-labeled target is inactivated when bound to the
antibody but can regain its activity upon displacement from the antibody by free
target in the sample. The active enzyme-labeled target can transform an
exogenous substrate to generate a signal dependent on free target concentration.
Thus, in the context of small molecule sensors, antibodies still do not offer direct
transduction (i.e., signal generation) of analyte-antibody interactions.
Aptamers are single-stranded oligonucleotide-based bio-affinity reagents which
mimic the specific recognition ability of antibodies but are chemically generated
and synthesized, overcoming the necessity for animal immunization while
providing unmatched reproducibility.8 Aptamers have been continuously improved
since the first generation back in 1990, with recent examples demonstrating
analytical performance surpassing antibodies.9 Aptamers are generated through
an artificial evolutionary process that screens >1013 unique sequences and only
evolves sequences that provide high specificity and high affinity for the target of
interest. The screening process can be customized to provide either exceptional
specificity or cross-reactivity for a family of molecules. For example, counterselection targets can be added to the process to remove sequences with affinity
for molecules with unwanted binding. Evolved aptamers can be accurately
3

sequenced and chemically synthesized with incredible reproducibility and purity.
Thus, aptamers always display the same inherent specificity and affinity regardless
of the source unlike antibodies. However, it should be noted that aptamer-target
interactions are dependent on experimental factors such as buffer conditions and
temperature, thus reproducibility also depends on the experimenter. Aptamers are
especially useful for detection of small molecule analytes with several
methodologies not requiring addition of exogenous reagents or multiple assay
steps. For example, Plaxco et al. described an aptamer-sensor that could be
implanted in ambulant animals to monitor small molecule drugs in real time.10
Aptamers can be engineered and chemically modified with functional groups for
signal transduction of the aptamer-analyte interaction, including analytical signal
via a change in color11,12, fluorescence13,14, or electrochemical current15,16.
Accordingly, aptamers have been utilized to develop biosensors for small
molecules including exogenous drugs of abuse, endogenous medical biomarkers,
and environmental toxins and pollutants.17
1.2

Motivation and goal

While the advantages of aptamer technology are well established, aptamer-based
sensors have not reached commercial availability because of issues including
limited sensitivity, inconsistent specificity (i.e., cross-reactivity) and susceptibility
to matrix interferents (i.e., selectivity).8 The goal of this dissertation is to understand
the physical characteristics of aptamer-target interactions and apply aptamer
engineering to increase aptamer-sensor sensitivity, specificity (i.e., crossreactivity) and selectivity (i.e., specificity against matrix interferents), resulting in
4

small molecule sensors that are functional in complex matrices. I describe methods
of aptamer engineering and innovations in signal transduction that display
improved analytical characteristics with specific examples including a cocaine
sensor that improved the detection limit of aptamer-based sensors by 50-fold, an
adenosine sensor that improved specificity against ATP, ADP and AMP and
simultaneously demonstrated a 40-fold improvement in sensitivity and a method
to generalize the aptamer engineering process for small molecule detection in
highly complex samples like serum.
1.3

Scope of the dissertation

To demonstrate the utility of aptamer-sensors for small molecule detection, I
present three projects that focus on rational aptamer engineering to improve the
sensitivity and specificity of current aptamers and outline a method to easily
generate aptamer-based sensors that can be utilized in complex samples such as
undiluted serum. Aptamer-based sensing of cocaine was previously limited
because of insufficient sensitivity. In chapter 3, I describe a simple fluorescence
aptamer-based sensor that I developed to detect cocaine in biological fluids and
other complex samples such as alcoholic and soft drinks, exhibiting detection limits
50-fold higher than other aptamer-based sensors, yet displaying near
instantaneous results, utilizing low cost reagents and microliter volumes. In chapter
4, I demonstrate the ability to engineer currently available aptamers to modulate
their specificity. The previously reported adenosine aptamer is cross-reactive for
multiple adenosine derivatives including adenosine, adenosine monophosphate,
adenosine diphosphate and adenosine triphosphate, molecules which are all
5

simultaneously present in biological fluids. The inherent cross-reactivity prevents
utilization of this aptamer for specific measurements of adenosine, a well-known
disease biomarker. An adenosine sensor is demonstrated that can instantaneously
detect adenosine in undiluted serum, providing a tool for disease diagnostics and
pathophysiological research. The sensor exhibits 40-fold higher sensitivity
compared to previously reported aptamer-based sensors with specificity against
ATP, ADP and AMP that has not been demonstrated elsewhere. Conventional
aptamer structures lack the structure-switching functionality required for
development of sensors applicable in complex samples. In chapter 5, I develop a
nuclease-guided system to intelligently truncate aptamer sequences yielding
aptamers which demonstrate optimal structure-switching functionality. The
produced aptamers can be easily incorporated to sensors functional in undiluted
complex

samples.

Specific

examples

include

truncation

of

an

methylenedioxypyrovalerone (MDPV)-binding aptamer, multiple steroid-binding
aptamers, and an adenosine triphosphate (ATP)-binding aptamer. In combination,
the body of work demonstrates the utility of aptamers for small molecule sensing,
the ability and tools to engineer aptamers to maximize sensitivity and specificity
and the adaptability of aptamers to methodologies that can be readily employed in
highly complex samples such as biological fluids.
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CHAPTER 2
Background and literature review
2.1 Biosensors
Biosensors are devices utilized to measure the presence or concentration of a
specific molecule in a sample solution. Biosensors are characterized by two main
components: the recognition and transducing elements.18–20 The recognition
element is the biomolecule component that provides discriminatory power for a
single molecule and a high affinity interaction that permits measurements of even
trace amounts of analyte. Recognition elements include enzymes, antibodies and
more recently, aptamers (i.e., DNA/RNA molecules). For example, pregnancy tests
utilize antibodies specific for human chorionic gonadotropin (hCG) to diagnose
pregnancy at home. Levels of hCG hormone rise rapidly and consistently after
implantation with concentrations peaking at 10,000-fold above basal levels.21–23
While recognition elements provide extensive discriminatory power and strong
interactions with a given molecule, they seldom transduce such an interaction into
a measurable signal. The transducing element can convert the interaction between
the recognition element and the analyte into a measurable signal. In the context of
the pregnancy test, multiple antibodies work in tandem to transduce binding of
hCG. The first antibody is immobilized on a test line and the second antibody is
labeled with gold nanoparticles which provide a color signal (fig. 1a). In the
presence of hCG, the two antibodies meet at the test line to form a sandwich
around the hCG molecule as they bind different epitopes of the molecule and a
colored line is observed on the test line from the gold nanoparticle-labeled antibody
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(fig. 1c and d, positive). In the absence of hCG, the line is not formed as the two
antibodies do not bind each other (fig. 1d, negative).24,25 A control line is also
included to signal the presence of the unbound antibody (fig. 1d). The recognition
element and the transducer determine the analytical performance of a biosensor.
The recognition element directly determines the specificity of the sensor while the
sensitivity is a function of both the recognition element but is also strongly
influenced by the transduction element. Biosensors are often characterized by the
type of recognition element that is employed.

Figure 1. Example of a biosensor for human chorionic gonadotropin (hCG) and its
utility in pregnancy diagnosis.
(a) Two antibodies specific for hCG are utilized. One antibody is immobilized on
the test line and a second antibody is covalently labeled with gold nanoparticles
for signal transduction. (b) Movement of the analyte and the labeled-antibody bring
the analyte near the immobilized antibody. (c) If hCG is present in the sample, it
will bind to the immobilized antibody and attract the secondary labeled antibody,
forming a sandwich complex with a color line appearing on the test line. In the
absence of hCG, the labeled antibody does not bind to the test line thus no color
is observed. A control line is also utilized which binds the labeled antibodies. (d)
Example results with a positive (two lines), negative (one line) and an intermediate
sample that might be difficult to interpret. (Adapted from Koczula et al.).25
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2.2 Antibody-based biosensors
Antibodies dominate the biosensor field because of their analytical performance
and wealth of methods available for detection of proteins and small molecules
directly in complex samples. Generation of antibodies is achieved through
repetitive immunization of an animal with a target of interest.2,26 Thus, production
of antibodies often requires several months of development and there exist
prevalent batch-to-batch variability and experimental reproducibility concerns that
have been well-documented in several articles.5,27 Binding interactions are often
described in terms of a dissociation constant –wherein the smaller the value, the
stronger the interaction– with antibodies demonstrating dissociation constants of 1
– 1,000 picomolar (10-12).27 Thus, antibody-based sensors are highly sensitive.
Once isolated, antibodies can be used in a variety of methods to couple the binding
interaction with an appropriate transduction mechanism. Small molecule detection
requires exogenous labeled-targets that act as signal markers and compete with
the free target for antibody binding sites.28 Thus, detection of a small molecule
analyte requires multiple steps and relatively high-cost. Commercial assays are
available for small molecules with assays including competitive enzyme-linked
immunosorbent assay (ELISA), homogenous enzyme linked immunoassays, and
kinetic interaction of microparticles in solution (KIMS).
2.2.1

Competitive enzyme-linked immunosorbent assay (ELISA)

All variations of ELISA assays require competition between a labeled-target or an
immobilized target with free target in the test sample for a limited number of
antibody binding sites.29 For example, the small molecule target can be passively
9

immobilized onto a plate surface. The unknown sample is mixed along with a
limited amount of the appropriate antibody and incubated in the microplate well.
Competition between the free target and the immobilized target will determine the
amount of antibody that is specifically absorbed onto the plate wall by binding to
the immobilized drug.30 If there is no drug present in the sample, most of the
antibody will bind to the well of the plate. If drug is present, the antibody will be
bound to the free drug and be discarded during the washing steps that remove
nonspecifically bound molecules. To quantify the amount of antibody left on the
plate wall, a secondary enzyme-labeled antibody is utilized with affinity for the first
antibody and an enzyme label such as horseradish peroxidase (HRP), which can
convert a substrate to give a signal.29,31 Several substrates are compatible with
HRP, and the absorbance of the solution can be read with a plate reader to
determine the drug concentration. The disadvantages of the assay are the long
incubation times required and the necessity for multiple washing steps.
2.2.2

Homogenous enzyme-linked immunoassays

These immunoassays utilize an enzyme-linked target and the inhibition of the
enzyme-linked target activity by antibody binding.32 A drug of interest is labeled
with an enzyme such as glucose-6-phosphate dehydrogenase (G6PDH), and
mixed with the sample of interest where the enzyme-labeled drug and the free drug
compete for a limited number of antibody binding sites.33 The drug concentration
is measured in terms of enzyme activity as it is modulated by binding to the
antibody relative to the concentration of free drug in the sample. When displaced
by free target binding to the antibody, the active enzyme converts nicotinamide
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adenine dinucleotide (NAD) to NADH, resulting in a change in the absorbance of
the solution that can be measured.33 The assay displays great sensitivity and
relatively fast detection but might suffer from cross-reactivity with off-target
molecules and high cost.33
2.2.3

Kinetic interaction of microparticles in solution (KIMS)

Microparticles are covalently modified with the drug of interest. In solution, these
microparticles are dispersed and do not block transmission of light. However, if
drug specific antibodies are added to the solution, it results in aggregation of the
microparticles because of organized lattice formation by binding interactions
between the antibodies and the drug-conjugated microparticles.7 The aggregated
particles effectively block light transmission through the sample, resulting in
increased absorbance.7 A sample that does not contain the drug of interest will not
change the absorbance of the sample. Samples that are drug positive will inhibit
the formation of the aggregated particles by competition for antibody binding sites
producing changes in the absorbance.34 The absorbance difference before and
after addition of sample can be utilized to calculate the drug content.34
2.3 Aptamers
Aptamers are chemically generated oligonucleotide-based recognition molecules
which mimic the binding specificity of antibodies for specific targets with highaffinity interactions but offer low-cost production, high reproducibility and ease of
chemical functionalization.39 Design of an aptamer-based biosensor from scratch
requires generation of an appropriate aptamer and adaption to a signal
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transduction mechanism. Aptamers have thus far been used to design biosensors
for small molecules, proteins, cells and ions.8 An incredible number of analytical
methodologies have been utilized in concert with aptamers to produce signaling
including electrochemistry, fluorescence, color-change, and mass-change
techniques.35–37
2.3.1

Discovery of aptamers and SELEX

The isolation of aptamers was first described by two independent research groups
in 1990. Tuerk and Gold termed the process of isolating such molecules as SELEX
(Systematic Evolution of Ligands by Exponential Enrichment) and Ellington and
Szostak coined the term aptamer –the output of SELEX (derived from Greek word
meaning to fit).38,39 The first SELEX experiment consisted of mutating part of a
sequence with a random 8-nt loop (each nucleotide position has a distinct
nucleotide A, T, C or G; thus 48 ~ 65,000 distinct sequences in the library). The
library of sequences was utilized to perform multiple rounds of competitive binding
and amplification of binding-competent sequences. The result was two sequences
that could bind the target from the starting library of 65,000.39 While initially met
with skepticism about the adaptability to other targets, SELEX has proven to be a
reliable method to isolate DNA/RNA molecules that can recognize several types
of targets including small molecules, proteins, and small ions.40,41
2.3.2

Systematic evolution by exponential enrichment (SELEX)42–45

The SELEX process consists of various steps to isolate a single binding sequence
from a rich and extensive set of unique aptamer sequences (termed a library). The
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library is made up of distinct oligonucleotide molecules (between 1013-15) with
constant primer regions (for amplification) and a variable region of random
nucleotides that vary in length to increase or fix molecular complexity (for binding
interactions).8 The library is incubated with the target (i.e., molecule of interest),
allowing for binding interactions between the aptamers and the target. The target
will naturally have an affinity for certain sequences that exhibit the maximum
interaction with the target based on the DNA fold or structure.26 The sequences
which bind the target are then separated from sequences that do not bind.
Separation can be accomplished by various mechanisms and is one of the main
differential factors of SELEX technologies. Separation can be achieved by
immobilization of the target onto a surface (see figure 2). The library is incubated
through a target-immobilized column and the binding aptamers are retained on the
column. Non-binding sequences are washed out and discarded while retained
aptamers are specifically eluted by addition of high concentrations of free target.
For small molecules, the immobilization utilizes an important functional group
which might prevent display of all functional groups of the target to the aptamer
library. To overcome the issue of immobilizing the target, the library can be
immobilized instead by hybridization to a column-conjugated complementary
strand.45 Addition of the target of interest results in displacement only of aptamers
that can undergo target-induced structure-switching from the hybridized
conjugated strand to a target-bound complex. The rest of non-binding and
immobilized aptamers can be discarded. The separation step is crucial as any nonbinding sequences must be discarded. Following separation, the remaining
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binding sequences are amplified by polymerase chain reaction (PCR). The PCR
reaction relies on enzymes to make copies of the remaining sequences in the
library. The binding sequences are amplified so the new library can have multiple
copies of a singular sequence, referred to as an enriched library. The PCR process
produces ds-DNA that must be separated into ss-DNA before the second round of
incubation with the target. Separation can be accomplished by primers that are
specifically labeled with affinity reagents such as biotin or with phosphate end
groups that are resistant to nuclease digestion. The enriched library of ss-DNA can
once again be incubated with the target. The same steps are followed for various
rounds of competitive binding until only the best binding sequences are present in
the enriched library. After each round of SELEX, elution profiles can be utilized to
determine whether the enriched library has increased in affinity to the target as
compared to the starting library and the library in the previous round. Thus, SELEX
has been regularly termed an artificial evolutionary process. Depending on the
SELEX methodology and the separation efficiency between binders and nonbinders, this can be from three to thirty rounds.8,17 Once the library has been
enriched, the remaining winning sequences are cloned and sequenced to
determine the exact nucleotide composition. The selection process can be done
completely in vitro, without requirements for animal immunization.27 Additionally,
the specificity of the aptamer can be carefully controlled by removal of sequences
which bind to undesirable molecules. The process yields aptamers that have high
specificity and sensitivity that can be applied for use in biosensors with unmatched
reproducibility if purity and reaction conditions are accurately controlled.
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Figure 2. Example schematic of target-immobilized SELEX. The target molecule
is immobilized on a surface and incubated with the DNA library. Non-binders are
washed out and the binders are eluted specifically and amplified via PCR. The
enriched library is utilized for a second round of separation. The selection rounds
are repeated until library enrichment is observed by affinity measurements after
each round. Once satisfactory enrichment has been achieved, the remaining
aptamer pool is cloned, sequence and characterized. (Adapted from Ruigrok et
al.).26
2.3.3 Aptamer-based sensors for small molecules
Aptamers have been utilized to measure various types of small molecules
including medical biomarkers, drugs of abuse, and therapeutic drug molecules.17
Importantly, aptamers can be synthesized or modified with added chemical
functionality which instills new properties apart from target recognition such as
direct signal transduction upon target binding.8 While well established, aptamer
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sensors for small molecules still suffer from insufficient sensitivity, inconsistent
specificity and difficulty in detection of analytes in complex samples.46 Aptamers
for small molecules generally exhibit equilibrium dissociation constants in the
micromolar range, about 100-fold lower as compared to antibodies.8,27 Thus, the
sensitivity of aptamer-based sensors is limited by the intrinsic aptamer affinity to
the targets and lack of appropriate transduction mechanisms that can maximize
the native affinity instead of reducing it. Additionally, several widely utilized small
molecule aptamers, such as the ATP-binding aptamer, exhibit cross-reactivity with
molecules that are simultaneously present in biological samples, preventing target
quantitation in biological samples.47 Finally, new methods are needed for universal
adaptation of currently reported aptamers to transduction mechanisms which can
function in complex matrices. Current methods rely on difficult, laborious and
expensive trial-and-error methodologies that are not convenient or universally
applicable.17,48
2.4 Cocaine
Cocaine is an illicit drug under the Controlled Substances Act with a designation
of schedule II; this designation is reserved for drugs that have little medical use
and an extremely high potential for abuse.49,50 Cocaine is a small molecule (<300
daltons) that still ranks as one the highest illegally consumed and trafficked drugs
in the world, according to the United Nations Office of Drug and Crime.51 Cocaine
affects individuals by inhibiting the reuptake of neurotransmitters in the reward
pathway such as dopamine. Drug effects produce exhilaration, euphoria,
increased heart rate, rage, and others.52,53 Apart from the wanted drug effects,
16

cocaine can cause severe health difficulties after prolonged and repeated
consumption such as organ failure.54 Thus, cocaine remains one of the most tested
drugs in law enforcement, criminal investigations and drug withdrawal programs.
Cocaine is quickly metabolized upon consumption with the major metabolite in
urine being benzoylecgonine.55,56 Benzoylecgonine is present in urine at
concentrations >100 mg/L for up to 24 hours after consumption while cocaine is
present at levels >65 mg/L in urine within 8 hours and at trace levels thereafter.56
Cocaine can also be found in saliva and serum at concentrations <0.4 mg/L. Thus
commercial immunoassays detect benzoylecgonine in urine rather than cocaine
as a presumptive test of cocaine use.33,56
2.4.1

Cocaine metabolite detection with antibodies

Various antibody-based assays are commercially available and widely employed
with a positive result cut-off level of 0.3 µg/L.33 The EMIT II assay employs a
glucose-6-phosphate

dehydrogenase

(G6PDH)

enzyme

conjugated

to

benzoylecgonine and benzoylecgonine specific antibodies for detection.32 If the
cocaine metabolite is present in a biological sample, the free benzoylecgonine will
compete for binding with the G6PDH-linked benzoylecgonine. The displacement
of G6PDH-linked benzoylecgonine leads to reactivation of enzymatic activity and
transformation of nicotinamide adenine dinucleotide (NAD) to NADH, resulting in
a change in the absorbance of the solution that can be measured via
spectroscopy.33 Competitive ELISA can also be employed for cocaine metabolite
detection. The method consists of immobilizing benzoylecgonine specific
antibodies onto a microplate well. A mixture of enzyme-labeled benzoylecgonine
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is then incubated on the microplate well with the tested sample. Competition for
the immobilized antibody binding sites is utilized to calculate the percent of labeled
drug that binds to the immobilized antibody. Other immunoassays for cocaine
metabolite

rely

on

similar

competition

mechanisms

between

labeled

benzoylecgonine and free benzoylecgonine in the sample matrix. These
immunoassay methods exhibit cross-reactivity that depends on the specificity of
the antibody and are susceptible to batch-to-batch variation. Additionally, the
antibodies must be carefully stored and transported and exhibit limited shelf life.
2.4.2

Cocaine detection with aptamers

The cocaine aptamer was isolated by Milan Stojanovic and co-workers in 2000.57
The original aptamer was termed MNS-4.1 and had a three-way junction
secondary structure. The three-way junction is a description of three distinct
intramolecular helices present around a central target-binding pocket. It has been
postulated that the binding pocket at the junction of the helices is a highly
hydrophobic environment because of unstacked nucleotides at the terminal of
each junction displaying hydrophobic surfaces to the internal pocket.58 The
isolated cocaine-binding aptamer has been utilized in several major sensor
categories: (1) as a fully stable and singular three-way junction aptamer in dyedisplacement assays, (2) as a singular, flexible aptamer in structure-switching
assays and (3) as a split structure wherein the aptamer is a composed of two
separate strands that can hybridize in the presence of cocaine.57,59,60 The latter
two categories suffer from limited sensitivity as it has been experimentally
determined that destabilizing or splitting of the aptamer structure reduces the
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binding affinity for cocaine.61,62 For example, Stojanovic et al. initially demonstrated
a fluorescence sensor by splitting the aptamer to produce target-induced selfassembly of the complementary fragments. One fragment was labeled with a
fluorescent molecule while the other fragment was labeled with a quencher
molecule. When cocaine was not present, the two fragments existed separately
and thus a high fluorescence signal could be measured. Cocaine would induce
self-assembly of the two fragments and bring the quencher near the fluorescent
molecule, turning off the fluorescent signal. In this way, cocaine could be detected
and differentiated from highly similar molecules, including benzoylecgonine which
varies at a single functional group. Unfortunately, splitting of the aptamer reduces
binding affinity for cocaine, limiting the sensitivity of the sensor. Stojanovic and coworkers later developed a more sensitive cocaine assay by stabilizing the threeway junction structure for a high affinity interaction with cocaine. They discovered
that the colorimetric dye Cy7 could bind to the binding pocket in the absence of
cocaine but was quickly displaced upon cocaine-aptamer specific binding,
resulting in change of the color of the solution.60 In this circumstance, the affinity
of the aptamer was conserved, leading to higher sensitivity as compared to the
split aptamer design. Thus, an important structural feature for cocaine sensing is
conserving or improving the high affinity interaction and coupling it with a sensitive
transduction mechanism. However, the strategy has not been regularly reported
with most transduction systems using cocaine-induced structure-switching
including electrochemistry, fluorescence, absorbance, and microcantilevers.60,63,64
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2.4.3

(2)-amino-5,6,7-trimethyl-1,8-naphthyridine (ATMND)

The small molecule ATMND is a fluorescent dye that was developed for DNA
single nucleotide polymorphism (SNP) typing. The ATMND molecule was
specifically designed to bind to nucleobases opposite an abasic site (a space
where a nucleotide is missing) by pseudo-hydrogen bonding to the unpaired
nucleobase opposite the abasic site and stacking interactions with the neighboring
nucleotides.65 Formation of hydrogen bonds and stacking in the DNA helix affects
the fluorescence of the molecule. Free in solution, ATMND is highly fluorescent
when excited at 358 nm. However, when bound inside the DNA helix, ATMND is
non-fluorescent.66 The base opposite the abasic site determines the binding affinity
of ATMND, with strong binding with cytosine (C) and thymine (T) but not but
Adenine or guanine (A and G).67 Abasic sites can be artificially incorporated onto
synthesized DNA or be mimicked by hybridization of DNA that leaves an empty
base site in the sequence, thus aptamers can be functionalized with a high-affinity
binding site for ATMND.68–70 Accordingly, ATMND has been utilized in various
aptamer-based assays as a fluorescence reporter.69–71 For example, Xiang et al.
developed an aptamer-sensor where ATMND is initially bound to an artificial
abasic site by hybridization of an aptamer sequence with a short-competing
oligonucleotide molecule. Target binding results in displacement of the hybridized
oligo, thus disrupting the binding site and displacing ATMND form the aptamer.
The fluorescence of the displaced ATMND can be correlated to the target
concentration.69,71 Additionally, ATMND was also found to bind to C-C mismatched
nucleotides in DNA stems, a property that has been exploited for detection of
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analytes via displacement of ATMND from the C-C binding site.72 These strategies
require chemical modification of the aptamer or addition of an anti-sense strand.
Modification of the aptamer reduces the inherent binding affinity of the aptamer
and limits the sensitivity of the assay.
2.5 Adenosine
Adenosine is an endogenous molecule present throughout the body with extensive
roles in extracellular signaling pathways.73 Adenosine is primarily but not
exclusively produced by metabolism of adenosine triphosphate, adenosine
diphosphate and adenosine monophosphate outside of the cell by transformation
of ATP to AMP by the enzyme CD39 followed by transformation of AMP to Ade by
CD73.74 Outside the cell, adenosine signaling functions by binding to four distinct
adenosine specific receptors: A1, A2a, A3, and A2b.73 Adenosine is the main agonist
of these receptors, initiating signaling pathways that affect immune response,
inflammation, blood flow and neurotransmitter release. Adenosine has been found
at physiological concentrations of 30 – 300 nM under physiological conditions but
at concentrations above 10 µM under pathological conditions (i.e., disease states)
such as cellular stress, cell damage, hypoxia and cancer.73,75–77 In cancer
pathogenesis, adenosine can act as an immunosuppressive signaling molecule by
binding to the A2a receptor.78 It has been shown experimentally that mice lacking
this receptor can recuperate from tumors, indicating the role of adenosine in
actively preventing activation of tumor preventing cells. As the role of adenosine in
immune response and inflammation needs to be explicitly understood, improved
tools to measure adenosine concentration are urgently needed.
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2.5.1

Adenosine concentration measurements

Current methods to measure adenosine concentration in biological samples
include high performance liquid chromatography (HPLC), capillary electrophoresis
(CE), micro-dialysis, and enzyme-based sensors.76,77,79 For example, HPLC can
readily detect adenosine with a simple absorbance detector as adenosine has a
distinct absorbance. More recently, HPLC has been coupled with mass
spectrometry to produce lower limits of detection and ability to measure more
complex samples.80 However, such methods cannot be used for real-time
detection, and also require complex sample handling and instrumentation.
Adenosine is quickly metabolized or transported inside of cells, thus real-time
monitoring of adenosine concentration might be better suited for more accurate
diagnostics.75 Additionally, adenosine concentration might vary close to the cell
surface, where adenosine is commonly produced. Thus, cell anchored recognition
elements might provide accurate concentration measurements of adenosine,
however such methods do not currently exist. The closest direct sensor for
adenosine is by use of enzymatic recognition. These sensors utilize enzymes that
can catalyze the transformation of adenosine into inosine, xanthine and other by
products eventually leading to the production of hydrogen peroxide, which can be
readily detected using electrochemistry or spectroscopy.81 Immobilization of these
enzymes inside a membrane bound to an electrode surface provides a sensor
methodology that can readily measure adenosine with much higher temporal
resolution and can be surgically implanted to measure adenosine in situ.
Unfortunately, insertion of these sensors into tissue causes damage that results in
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release of ATP and thus affects the actual physiological concentration of
adenosine. These sensors are also prone to interference from endogenous
molecules such as inosine and xanthine, which are commonly found in biological
fluids.81,82
2.5.2

Aptamer-based adenosine measurements

Huizenga et al. isolated the ATP-binding aptamer in 1995.47 The aptamer can bind
to

multiple

adenosine

derivatives

including

adenosine,

adenosine

monophosphate, adenosine diphosphate, and adenosine triphosphate.47,83
Unfortunately, these molecules are simultaneously present in biological fluids.84,85
Therefore, the current ATP-binding aptamer cannot be utilized for specific
determinations of adenosine concentration in complex samples or clinically
relevant diagnostics. Most publications have utilized the ATP-binding aptamer as
a test bed for a transduction method rather than attempting to address the issue
of specificity. For example, Lu et al. developed a sensor that used time-resolved
luminescence for detection of adenosine in undiluted serum samples.46 However,
the method displayed cross-reactivity with adenosine phosphate derivatives and
displayed limited sensitivity (60 µM). Only one reported aptamer structure is
specific for adenosine against negatively charged phosphate derivate molecules.
Stojanovic et al. isolated an adenosine binding aptamer that was engineered to
provide significant binding affinity for adenosine and decrease affinity with linear
phosphate derivatives because of steric repulsion as argued by the authors.
However, the Stojanovic aptamer structure has not been studied in detail and its
application for complex sample measurements has not been determined.86
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2.5.3

Aptamer engineering

An important aspect of aptamer-sensor development is the need to instill signal
reporting functionalities to aptamers and to fine-tune the affinity and specificity of
the aptamer. Aptamer engineering can include mutation of nucleotides in the
sequence, addition of nucleotides or removal of non-essential nucleotides.47
Several examples in the literature have demonstrated increased aptamer
performance after aptamer engineering.48,86,87
2.5.4

Electrochemical aptamer-based (E-AB) sensors

Electrochemical detection of molecules by linking with aptamer recognition is an
extremely powerful technology that can be utilized in complex samples such as
whole blood.10,88 The technique was inspired by electrochemical detection of DNA
via immobilized DNA probes mimicking molecular beacons that were covalently
labeled with a ferrocene tag which is an electroactive molecule.89 In the absence
of DNA target, the immobilized stem-loop probe keeps the ferrocene tag near the
electrode surface, with large currents being measured. Binding of the immobilized
probe to a target DNA resulted in formation of double-stranded DNA structures that
separated the electroactive group from the electrode surface. The distance directly
affected the rate of electron transfer between the electroactive molecule and the
electrode surface, thus the change in current could be used to determine the
amount of DNA bound to the immobilized probe.89 Soon thereafter, aptamers were
immobilized onto electrode surfaces (via strong thiol-gold bonds) and covalently
labeled with methylene blue, an electroactive molecule.90 Xiao et al. first developed
a signal-off sensor where the immobilized aptamer was separated from the
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electrode surface by binding to thrombin (a relatively large molecule), resulting in
reduced mobility of the aptamer and a reduction in the measured current.91 The
native aptamer structure can also be engineered to maintain a flexible and open
conformation which places the electroactive molecule far from the electrode
surface, inhibiting the transfer of electrons.92 Target-binding can induce aptamer
folding around the target causing the electroactive molecule to approach the
surface and increase the rate of electron transfer. Thus, the current measured
increases as target is added to the solution.93 An important aspect of E-AB sensors
is the preparation of the aptamer-immobilized electrode.94 The aptamer is
immobilized by addition of a thiol chemical group to one end of the aptamer. Gold
electrodes can then form strong bonds with the thiol group, causing immobilization
of the aptamer to the gold surface.95 While the thiol-gold bond is very strong, the
nitrogenous bases of the DNA sequence are known to weakly interact with the gold
surface.96 Thus, short alkane-thiol molecules can be added to prevent adsorption
of the nitrogenous bases to the electrode surface.95 These short molecules form
strong interactions with the gold surface and organize in neat monolayers because
of hydrophobic interactions between the alkane chains of the immobilized
molecules. Their role is to keep the aptamers in a ‘standing’ direction by preventing
absorption of the nitrogenous bases to the electrode surface and to carefully
control the density of immobilized aptamers at the electrode surface.95,97,98 Once
prepared, the aptamer-bound electrodes can be utilized repeatedly by directly
submerging into a sample of interest. A voltage is applied to the electrode to
interrogate the electroactive molecule and measure the resulting current.
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2.6

Aptamer structure-switching

Aptamer isolation techniques often utilize libraries that have highly stable
secondary structures with static conformations, requiring substantial testing to
affirm or instill structure-switching upon target binding.17,48,62,83 Lack of structural
change prevents adaptation to signaling mechanisms, as most require significant
differences between the target-free structure and target-bound structure. Aptamer
truncation describes a general process of removing nucleotides in the aptamer
sequence that are not essential for binding, destabilizing the structure and instilling
structure-switching functionality to the truncated aptamer.48,62,99 Aptamer
truncation can be attained by manually removing bases from various parts of the
aptamer to deduce the primary binding site but it is laborious and expensive
because it requires characterization of multiple aptamer derivatives. Generally,
most techniques rely on similar trial-and-error mechanisms until a short aptamer
sequence is identified.17,100,101 For example, the cocaine aptamer was previously
engineered to destabilize the target-free structure, with aptamer folding only
occurring when cocaine was bound to the aptamer.102 The signaling occurred
through a fluorescent label that was attached to one end of the aptamer and a
quenching molecule attached to the opposite end. In the absence of cocaine, the
two molecules were spatially separated but upon target-binding the molecules
were in proximity. Thus, cocaine could modulate the fluorescence signal although
affinity was compromised because of destabilization of the aptamer binding site.
While functional, this technique is not easily adapted to other aptamers, requiring
extensive work to deduce the target binding site and the minimum number of
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nucleotides to provide binding affinity to the target. Therefore, other ways have
been developed to instill structure-switching functionality. For example, a short
complementary DNA strand can be used to hybridize with part of the aptamer
sequence and block the binding site of the analyte.83 The length of the competing
sequence is carefully designed to allow target-induced displacement. If the length
of the competitor sequence is too long, the target would not be able to displace the
competitor. While this method is easier to use with various aptamers, there is
severe reduction in the affinity of the aptamer to the target because of the inherent
competition imposed by the competing DNA strand.46,83
2.6.1

Nuclease-guided truncation of aptamers

Several purified enzymes are commercially available for a wide range of
applications in transformation of DNA molecules. These enzymes often display
incredible specificity for a specific structure of DNA, such as double-stranded DNA
or single-stranded DNA. Thus, these enzymes can be utilized to probe the changes
in the DNA conformation upon target-binding.
2.6.2

Exonuclease I (Exo I)

Exonuclease I is an enzyme purified from E. coli with a high level of specificity for
hydrolysis of single-stranded DNA but with little to effect on double-stranded
DNA.103 The enzyme can hydrolyze ss-DNA from the 3’- end stepwise, releasing
single mononucleotides. The enzyme requires a divalent cation for catalysis and
optimally performs under basic conditions. The enzyme has been previously
utilized to detect small molecules with aptamer recognition.104 In the absence of
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target, the aptamers have a conformation that is hydrolyzed by Exo I however upon
binding to the target, the aptamer-target complex is not susceptible to enzymatic
digestion. Addition of SYBR gold DNA binding dye was utilized to measure the
amount of aptamer product left and correlated with the concentration of target.
2.6.3

Exonuclease III (Exo III)

Exonuclease III is an enzyme purified from E. coli that can catalyze the hydrolysis
of various types of DNA. Exonuclease III can perform activities such as digestion
of double-stranded DNA from the 3’- end of DNA, at blunt ends or at recessed 3’ends but is not able to digest 3’- extensions longer than 4 nucleotides.105,106 The
digestion results in release of mononucleotides and formation of single stranded
DNA. Exonuclease III also displays endonuclease activity at abasic sites, resulting
in nicks of the DNA sequence and formation of separate DNA fragments, and
phosphatase activity for cleaving phosphate 3’ ends to 3’-OH, as well as Rnase H
activity for catalyzing the hydrolysis of RNA/DNA hybrids.107,108
Exonuclease III has been employed to truncate aptamer sequences to yield
structure-switching aptamers and also to determine the binding sites of proteins to
DNA. Such footprinting studies were based on the inhibition of the enzyme as it
approached the protein-DNA binding site, producing leftover DNA fragments that
could be visualized via gel electrophoresis to approximate the binding site by
comparison to a control sample.109 A similar inhibition effect was discovered by
Wang et al. where formation of aptamer-target complexes can inhibit the hydrolysis
of aptamers by exonuclease III 4-nt away from the presumed binding site. In the
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absence of binding target, exo III can completely digest the aptamer molecule.
Furthermore, the yielded truncated aptamer sequences were shown to undergo
target-induced structure-switching. The method demonstrated a general and
simple platform to truncate stable, folded aptamers to yield structure-switching
capable aptamer sequences.110
2.6.4

T5 exonuclease

The enzyme T5-exonuclease can preferentially digest 5’ overhangs, flaps and
linear single- and double-stranded DNA in the 5’ to 3’ direction.111 The enzyme
structure has been previously elucidated, with a small opening that is big enough
to allow the threading of single-stranded DNA but not double-stranded DNA.112
The enzyme T5 can bind to a 5’ overhang and thread the single-stranded
sequence through the active site arch until reaching a junction of double-stranded
DNA. The enzyme then hydrolyzes the threaded DNA resulting in a blunted dsDNA
and a single-stranded fragment. The active site of the enzyme is lined with
hydrophobic residues that presumably stabilize the threading of single-stranded
DNA, and binding of divalent ions at the active site that mediate the hydrolysis
reaction.113 A variety of divalent metal ions can be used as cofactors of T5
exonuclease, with different ions modulating the activity of the enzyme.114 T5
exonuclease has been described as a complementary enzyme to exonuclease III,
which has similar activity but in the 3’ to 5’ direction. Exonuclease III has been
utilized for determination of the binding site of molecules to DNA, thus it is possible
that T5 exonuclease could perform a similar function.
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2.6.5

Methylenedioxypyrovalerone (MDPV)

The drug MDPV is an illicit substance under the Controlled Substances Act. It is
listed as a schedule I drug with a high potential for abuse and no known medical
use. The drug was initially part of the ‘bath salt’ epidemic, commonly sold as a
product not meant for human consumption at convenience stores or over the
Internet.115 The effect of MDPV is mediated by inhibiting dopamine reuptake and
thus creating exhilaration with similar effects as drugs like cocaine and
amphetamine.116 The common dosage of MDPV is in the milligram range and can
be consumed in various ways such as snorting or smoking. Long term effects apart
from addiction are not widely known although like cocaine, inhibition of the reward
uptake pathway can have damaging health consequences.117 Detection of MDPV
is an increasing concern for law enforcement and health administration. Antibodybased tests are available for screening of MDPV, with common confirmatory
methods including GC/MS and other chromatography-mass spectrometry
methods.118,119 However, MDPV is part of a family of drugs that have been
extensively modified to avoid detection. Unfortunately, current immunoassays only
recognize few structures thus new assays are urgently needed to screen the drug
family rather than a single molecule specifically.120
2.6.6

Adenosine triphosphate (ATP)

Adenosine triphosphate (ATP) has various roles in cell signaling such as
inflammation and immune response .74 Adenosine triphosphate is present
intracellularly (i.e., inside the cell) at relatively high concentrations, between 5-10
mM.121 The ATP molecule is amphiphilic, with hydrophobic groups as a result of
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the nitrogenous base and hydrophilic because of the highly charged phosphate
groups. A recent report suggest that the high intracellular concentration of ATP is
because of the role of ATP as a hydrotrope, a compound that can facilitate
solubilization

of

hydrophobic

compounds.121 Adenosine

triphosphate

is

transported to the outside of the cell by specific channel transporters and
exocytosis.122 Outside the cell, it effects its signaling function by binding to a wide
range of ATP receptors (termed P2 receptors).123 Its cellular signaling affects
mechanisms such as inflammation and immune response. ATP can be reliably
measured by the luciferase reaction. Luciferase can utilize ATP to oxygenate
luciferin, producing light as a result.84 ATP concentration can be measured by the
amount of light that is produced. More recent reports have outlined a method to
immobilize this enzyme to cell membranes, permitting in situ measurements of
ATP concentration in real time.124 Aptamer-sensors have also been designed for
specific detection of ATP albeit with high dissociation constants and crossreactivity with ADP.125

31

Adapted with permission from Analytical Chemistry. 86, 22, 11100-11106.
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CHAPTER 3
A Label-Free Aptamer-Fluorophore Assembly for Rapid and Specific
Detection of Cocaine in Biofluids
We report a rapid and specific aptamer-based method for one-step cocaine
detection with minimal reagent requirements. The feasibility of aptamer-based
detection has been demonstrated with sensors that operate via target-induced
conformational change mechanisms, but these have generally exhibited limited
target sensitivity. We have discovered that the cocaine-binding aptamer MNS-4.1
can also bind the fluorescent molecule 2-amino-5,6,7-trimethyl-1,8-naphthyridine
(ATMND) and thereby quench its fluorescence. We subsequently introduced
sequence changes into MNS-4.1 to engineer a new cocaine-binding aptamer (38GC) that exhibits higher affinity to both ligands, with reduced background signal
and increased signal gain. Using this aptamer, we have developed a new sensor
platform that relies on the cocaine-mediated displacement of ATMND from 38-GC
as a result of competitive binding. We demonstrate that our sensor can detect
cocaine within seconds at concentrations as low as 200 nM, which is 50-fold lower
than existing assays based on target-induced conformational change. More
importantly, our assay achieves successful cocaine detection in body fluids, with
a limit of detection of 10.4, 18.4, and 36 μM in undiluted saliva, urine, and serum
samples, respectively.
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3.1 Introduction
Cocaine is a central nervous system stimulant that increases levels of
dopamine126,127 and potently inhibits neurotransmitter reuptake at the synapse.128–
132

Abuse of cocaine has been shown to cause anxiety, paranoia, mood

disturbances, organ damage, and violent behavior.52,133,134 Therefore, rapid
detection of cocaine is needed to confirm suspicion of recent use in impaired driver
investigations or to assist in overdose treatment in medical emergency settings.
Various immunoassays have been developed for the detection of cocaine and/or
its major metabolite benzoylecgonine in biofluids, including the enzyme-linked
immunosorbent assay (ELISA)135 and the EMIT II Plus Cocaine Metabolite
Assay.136 Unfortunately, the use of these assays is often limited because of the
high cost of generating antibodies and issues with poor specificity. These antibodybased tests often cannot distinguish between the targeted drug and structurally
similar substances, resulting in cross-reactivity-related false positives.137,138
Aptamers are single-stranded RNA or DNA molecules selected in vitro via
Systematic Evolution of Ligands by Exponential Enrichment (SELEX)39 to
specifically bind to targets with high affinity, and they offer a practical alternative to
antibodies for the detection of nucleic acids, proteins, and small molecules.
Compared to antibodies, aptamers are relatively fast and cheap to produce and
can be chemically synthesized with extreme accuracy and reproducibility.26,139
Aptamer-based sensors have been gaining popularity because of their simplicity
and specificity. For example, derivatives of the MNS-4.1 cocaine-binding
aptamer57 have been labeled with sensing elements such as fluorophore/quencher
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pairs,59 magnetic or metallic nanoparticles,11,140,141 quantum dots,142,143 and
methylene blue64,144 to achieve specific detection of cocaine. In the absence of
cocaine, the aptamer population exists in an equilibrium state consisting of both
folded and unfolded structures,62 where the folded structures generate a
background signal. When challenged with cocaine, the unfolded aptamers
undergo a target-induced conformational change and form a noncanonical threeway junction that binds cocaine,62 producing a signal change. This limited targetinduced fluorescence change resulted in a high detection limit (10 μM) even under
optimal conditions, and the reason may be due to inefficient proximity quenching,
low aptamer-target binding affinity, or both.59
Different strategies such as target displacement have been used to increase the
sensitivity of aptamer-based detection. For example, Stojanovic’s group used
unmodified MNS-4.1 (Figure 3, MNS-4.1) to construct a colorimetric cocaine
sensor

based

on

cocaine-mediated

displacement

of

a

cyanine

dye

(diethylthiotricarbocyanine iodide; Cy7) from the dye-aptamer complex.60 They
observed that the absorbance of Cy7 at 760 nm decreased with increasing cocaine
concentrations in the range of 2 to 600 μM. Compared to the corresponding
fluorescence sensor that exhibited less sensitivity due to intrusive covalent
modifications on the aptamer,59 the sensitivity of the Cy7-based displacement
assay was improved due to the high binding affinity of the unmodified MNS-4.1
aptamer for cocaine.59,60,145 However, the limit of detection of this sensor was still
limited to 2 μM as a result of high background signal from the weak interaction
between Cy7 and MNS-4.1.60
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Figure 3. (Top) Structures of the MNS-4.1, 38-GT, and 38-GC aptamers.
These aptamers are predicted to fold into three helical stems built around a threeway junction. Stem 1 of MNS-4.1 contains three putative noncanonical base pairs,
which have been substituted for Watson–Crick base pairs in 38-GT. 38-GC was
further stabilized by converting the G–T wobble pair in stem 3 to a matched G–C
base pair. (Bottom) Scheme of cocaine detection with the 38-GC aptamer sensor.
38-GC stably folds in the absence of ligand at room temperature. ATMND binding
to the aptamer quenches the molecule’s fluorescence, but after challenging this
complex with cocaine, the competitive binding displaces ATMND from the binding
site. The released ATMND generates a readily detectable fluorescent signal,
indicating the presence of the cocaine target.
In this work, we found that the MNS-4.1 cocaine binding aptamer can also bind the
fluorescent dye 2-amino-5,6,7-trimethyl-1,8-naphthyridine (ATMND), quenching
its fluorescence. In the presence of cocaine, however, the bound ATMND is
competitively displaced, generating a rapid fluorescent readout as the released
molecule is highly fluorescent in solution. Based on our characterization of this
competitive binding of the cocaine target and ATMND signal reporter to the same
aptamer, we further improved the performance of our aptamer sensor by deriving
a new variant (Figure 3, 38-GC) of MNS-4.1 that stably assumes a predominantly
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folded conformation at equilibrium. Using this optimized aptamer, we developed a
rapid and selective assay for the detection of cocaine at concentrations as low as
200 nM within 20 seconds, ∼50-fold lower than assays based on target-induced
conformational

change,140 but

in

less

time

and

with

fewer

reagent

requirements.146–148 Importantly, our sensor can also rapidly achieve cocaine
detection at micromolar concentrations in body fluids such as urine, saliva, and
serum.
3.2

Materials

ATMND was purchased from Ryan Scientific, and 3,3′-diethylthiatricarbocyanine
iodide (Cy7) was purchased from Sigma-Aldrich; any dilution or stock solution was
prepared with dimethyl sulfoxide (DMSO). Cocaine hydrochloride was purchased
from Sigma-Aldrich, and benzoylecgonine tetrahydrate was purchased from
Cerilliant Corporation. Both 50 mM stock solutions were prepared in acidic
deionized water solution (pH 4.5) and stored at 4 °C. All DNA aptamers were
ordered from Integrated DNA Technologies with high performance liquid
chromatography (HPLC) purification and dissolved to a concentration of 500 μM in
1 × filtered Tris-EDTA buffer (10 mM Tris, 1 mM EDTA, pH 8.0). DNA
concentrations were measured on a NanoDrop 2000 (Thermo Scientific). DNA
sequences are listed below:
•

38-GT: 5′ GGG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CTC CC
3′;

•

36-GT: 5’ GG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CTC C 3’;
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•

34-GT: 5’ G AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CTC 3’;

•

32-GT: 5’ AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CT 3’;

•

30-GT: 5’ GA CAA GGA AAA TCC TTC AAT GAA GTG GGT C 3’;

•

38-GC: 5′ GGG AGA CAA GGA AAA TCC TTC AAC GAA GTG GGT CTC CC
3′;

•

38-GC M1: 5′ GGG AGA CAA GGA AAA TCC TCT AAC GAA GTG GGT CTC
CC 3′;

•

38-GC M2: 5′ GGG AGA CAA GGA AAA TCC TAC AAC GAA GTG GGT CTC
CC 3′;

•

MNS-4.1: 5′ GGG AGA CAA GGA TAA ATC CTT CAA TGA AGT GGG TCG
ATA 3′

3.3 Methods
ATMND Binding and Cocaine Displacement Experiments
For cocaine detection, we prepared 96 μL of reaction buffer (10 mM Tris, 0.01 mM
MgCl2, pH 7.4), 1 μL of aptamer (final concentration 2 μM), and 1 μL of ATMND
(final concentration 0.25 μM) solution. Each 98 μL reaction was loaded into one
well of a 96-well plate. Fluorescence readings were taken 3 min apart to determine
the stability of the signal, with excitation at 358 nm and emission at 405 nm. After
the signal stabilized for 15 min, a 2 μL cocaine solution (0–2.5 mM) was added to
each well using a multichannel pipet while monitoring the fluorescence signal.
Samples were prepared in triplicate with average values used to plot the figures.
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3.3.1

Detection with Cy7

We performed the same set of experiments with the same solutions as described
above for ATMND, but with 1 μL (final concentration 7 μM) of Cy7 instead of
ATMND. The absorbance was recorded at 760 nm.
3.3.2

ITC Experiments

ITC experiments were performed with a MicroCal iTC200 instrument (GE
Healthcare). All measurements were performed in 10 mM Tris buffer (pH 7.4) with
0.01 mM MgCl2 and 5% DMSO. The sample cell contained the aptamer solution,
while the titrant was loaded in the syringe. In order to detect tight binding, the
aptamer concentration was kept at 20 μM while the titrant (cocaine or ATMND)
concentration was 500 μM. We introduced 19 total injections of 2 μL each and a
purge injection of 0.4 μL. The purge injection was not included in the calculations.
Two sets of each experiment with cocaine or ATMND were performed at 25 °C.
The raw data were averaged and fitted to the two sets of sites and single-site
binding models and adjusted for the heat of the titrant.
3.3.3

Detection of Cocaine in Urine, Serum, and Saliva

Different concentrations of biofluids were obtained by dilution with deionized water.
To test the quenching effect of biofluids, we mixed ATMND (500 nM) in 2× reaction
buffer (20 mM Tris, 0.02 mM MgCl2, pH 7.4) with an equal volume of biofluids,
followed by fluorescence measurements. To test the signal gain of cocaine in
different biofluid dilutions, we spiked cocaine (500 μM) into 50%, 25%, 10%, 5%,
and 0% urine, serum, and saliva. These were then mixed with an equal volume of
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2× reaction buffer containing ATMND (500 nM) and 38-GC (4 μM), followed by
subsequent fluorescence recording. To perform cocaine detection in biofluids,
different cocaine concentrations were spiked into 5% urine, 5% serum, or 10%
saliva. Equal volumes of cocaine-spiked biofluids and 2× reaction buffer containing
ATMND (500 nM) and 38-GC (4 μM) were mixed to read the fluorescence. Unless
otherwise indicated, fluorescence measurements were obtained with excitation at
358 nm and emission at 405 nm.
3.4

Results and discussion

We devised our platform based on cocaine-mediated displacement, employing an
aptamer sensor that reports the presence of cocaine via the displacement and
unquenching of a bound fluorophore molecule. In the absence of ligand, the
cocaine binding aptamer forms three helical stems around a three-way junction.
ATMND binds the aptamer at this junction, which results in the quenching of its
fluorescence (Figure 3B). Since this aptamer also binds cocaine, the competitive
binding of cocaine results in a rapid displacement of the ATMND from the aptamer.
The released ATMND generates a high-intensity fluorescent signal, reporting the
cocaine-binding event.
To develop a cocaine displacement-based sensor platform, we need a signal
reporter which binds to the cocaine-binding aptamer but can also be displaced by
cocaine, reporting the presence of the target. We recently discovered that the
MNS-4.1 cocaine binding aptamer can also bind to the fluorophore ATMND and
the cocaine binding can competitively displace ATMND from the aptamer–dye
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complex. Free ATMND is highly fluorescent in buffer, but ATMND is rapidly bound
by MNS-4.1 upon addition of the aptamer, and we observed that ATMND
fluorescence was greatly quenched within seconds. When we incubated 250 nM
ATMND with 2 μM MNS-4.1, roughly 93% of the fluorescent signal was quenched,
with the remaining 7% contributing to the low level of fluorescence background
(Figure 4A). The aptamer–ATMND complex is very stable, and we did not observe
any detectable fluorescence change over the course of 1 hour. We characterized
sensor performance in terms of signal gain, which is the ratio of the backgroundsubtracted fluorescence obtained with cocaine relative to that obtained in the
absence of cocaine, such that a larger signal gain is indicative of better sensitivity.
The addition of cocaine is predicted to trigger a conformational rearrangement in
the aptamer (Figure 3B), with two adjacent GA base pairs and a dinucleotide bulge
(T20 and C21) within the aptamer binding pocket.62 Upon 50 μM cocaine addition,
we observed a competitive target binding to MNS-4.1, resulting in successful
displacement of ATMND from the aptamer with a signal gain of 9.6 (Figure 4A).
This fluorescence increase was stable for at least several hours (data not shown).
We assume that this competitive binding results from a pure site-to-site
displacement, although it could also be explained by a heterotropic allosteric effect.
In contrast, we observed no measurable signal change in the absence of cocaine
(Figure 4A).
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Figure 4. Our aptamer-based sensor rapidly responds in the presence of cocaine.
(A) Time course of ATMND release. ATMND in buffer is highly fluorescent when
excited at 358 nm. ATMND is rapidly bound upon addition of the cocaine-binding
aptamer, resulting in quenching of its fluorescence. In the presence of cocaine, the
release of ATMND results in recovery of a strong fluorescent signal. (B) The impact
of aptamer stability on signaling performance. The signal gain observed in the
presence of cocaine was dependent on the composition of stem 1 and stem 3,
which contributes to aptamer stability and ATMND/cocaine binding. Experimental
conditions: [DNA] = 2 μM, [ATMND] = 250 nM, [cocaine] = 50 μM. Error bars
represent the standard deviation of three measurements.
Previous studies have suggested that the composition of stem 1 of the cocainebinding aptamer has the greatest impact on the secondary structure of the aptamer
as well as the target binding affinity.62 MNS-4.1 is only partially folded at
equilibrium,60 and this is most likely due to the presence of three noncanonical
base pairs in stem 1, which would be expected to reduce the efficiency of ATMND
binding and quenching and thereby result in high background fluorescence.
Neves’s group62 used 2D NMR spectral changes to confirm that the cocainebinding aptamer with six Watson–Crick base pairs in stem 1 is fully folded in the
free form and exhibits increased binding affinity as compared to the original MNS
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4.1 aptamer. To test whether such a completely folded aptamer could reduce
background fluorescence and boost signal gain, we engineered the 38-GT
aptamer (Figure 3, 38-GT) by converting the three putative noncanonical base
pairs in stem 1 to Watson–Crick base pairs, forming a seven-base-pair stem.
Additionally, we tested whether decreasing the length of the stem would result in
destabilization of the aptamer structure and studied the effects of such nucleotide
deletions to the sensor performance. Interestingly, increasing the length of the
stabilizing stem led to higher fluorescence quenching of a constant concentration
of ATMND with little quenching being observed with an aptamer sequence with a
short (3-base pair) stem 1 (Figure 5). These results suggest that binding of ATMND
requires formation of the hydrophobic three-way junction pocket that can host the
ATMND fluorophore, with increasing folding of the aptamer resulting in better
binding of ATMND. The 38-GT (seven base-pairs in stem 1) resulted in reduced
background fluorescence, with 95% ATMND quenched (data not shown),
indicating that ATMND binds tightly to 38-GT. We did not observe any loss of
cocaine-displaced signal and obtained an increased signal gain of 12 in the
presence of 50 μM cocaine (Figure 4B). To further reduce the background signal,
we subsequently converted the G–T wobble pair in stem 3 of 38-GT to a matched
G–C base pair (Figure 3, 38-GC). This increased structural stability led to a further
increase of ATMND quenching efficiency (97%) and an improved signal gain of 17
(Figure 4B) with 50 μM cocaine.
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Figure 5. Stem-length effects on fluorophore binding and displacement by
cocaine.
Various aptamer sequences were studied with increasing length of the structure
stabilizing stem 1 from three base-pairs to seven base-pairs. Additionally, a seven
base-pair sequence was further mutated by changing a non-match base-pair in
stem 3 to a fully matched Watson-crick helix (termed 38-GC). Increasing the length
of the stabilizing stem led to higher fluorescence quenching of a constant
concentration of ATMND suggesting that formation of the three-way junction is
necessary for binding of ATMND to the aptamer structure. The highest fluorescent
quenching was observed with the 38-GC sequence which has the most stable and
folded structure. [DNA] = 2 µM, [ATMND] = 250 nM, Ex: 358 nm; Em: 405 nm.
We presume that the greatly enhanced stability of 38-GC contributes to its high
affinity toward both ligands, favoring formation of stable aptamer–ligand
complexes and resulting in low background and high target-displaced signal gain.
We used isothermal titration calorimetry (ITC) to investigate the binding affinity and
thermodynamics of MNS-4.1, 38-GT, and 38-GC with regards to both ATMND and
cocaine. The results confirmed that the aptamers bind both molecules, and that
binding in both cases is enthalpically driven and entropically unfavorable (Table
1). ITC stoichiometry data indicated that each aptamer binds to one cocaine
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molecule or two ATMND molecules. After correction of the dilution heat, we used
the single-site binding model to obtain equilibrium dissociation constants (Kdc) of
6.7 ± 1.3 μM (Figure 6A), 10 ± 1 μM (Figure 6C) for cocaine binding to MNS-4.1
and 38-GT, respectively. Interestingly, affinity for cocaine is essentially unchanged
even after stabilization of the aptamer structure with completely matched helix in
stem 1. We used the two sets of sites binding model to obtain affinity
measurements for ATMND binding sites on MNS-4.1 (Kd1, 6.6 ± 0.8 μM; Kd2, 25 ±
1 μM) (Figure 6B) and 38-GT (Kd1, 0.16 ± 0.08 μM; Kd2, 6.3 ± 1.2 μM) (Figure 6D).
In contrast to cocaine binding, ATMND affinity increases substantially after
substitution of the mismatched base-pairs in stem 1 with a completely matched
helix. Accordingly, the higher levels of fluorescence quenching are observed
presumably because of the higher affinity of ATMND to the more stable fully
matched helix as observed from the fluorescence experiments. ITC data also
showed that the G–C change in 38-GC further increases the stability of the
aptamer, leading to increased binding affinity for both ligands. Compared with 38GT, we observed 4-fold enhanced binding to cocaine (Kdc = 2.6 ± 1.0 μM) and 10fold tighter binding to ATMND (Kd1 = 0.016 ± 0.001 μM; Kd2 = 2.6 ± 1.0 μM) (Figure
7). The thermodynamics of binding indicate that the binding of both molecules is
highly enthalpically driven. This suggests strong hydrogen bonding interactions
upon binding of both molecules. Interestingly, cocaine binding results in higher
levels of enthalpy change. This is presumably because cocaine binding can induce
changes in the aptamer conformation, resulting in creation of new hydrogen bonds.
Unlike cocaine, ATMND does not affect the structure of the aptamer, but rather
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might just reside in the 3-way junction pocket of the host aptamer and hydrogen
bond with unpaired nucleotides in the absence of cocaine.
Table 1. Binding and thermodynamic parameters of 38-GT and 38-GC for ATMND
and cocaine*

*Data obtained at 25°C in 10 mM Tris (pH 7.4) + 0.01 mM MgCl2 + 5% DMSO. The
values reported are averages of three individual experiments with one standard
deviation.
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Figure 6. ITC data demonstrated that MNS-4.1 and 38-GT binds both cocaine and
ATMND.
ITC data showing heat generated from each injection of (A) cocaine or (B) ATMND
into the MNS-4.1 aptamer solution. (C, D) ITC data showing heat generated from
each injection and integrated heat plot of (C) cocaine or (D) ATMND into the 38GT aptamer solution. Experimental conditions: [MNS-4.1 or 38-GT] = 20 µM,
[ATMND] = 500 µM and [cocaine] = 500 µM. Binding experiments were performed
in 10 mM Tris (pH 7.4) including 0.01 mM MgCl2 and 5% DMSO at 25 °C.
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Figure 7. 38-GC binds both cocaine and ATMND.
(Top) ITC data showing heat generated from each injection of (A) cocaine or (B)
ATMND into the 38-GC solution. (Bottom) The integrated heat plot after correcting
for the heat of dilution. Experimental conditions: [38-GC] = 20 μM, [ATMND] = 500
μM, and [cocaine] = 500 μM.
These results demonstrate the potential of ATMND as an excellent transduction
element; its tight binding to the aptamer results in a very low background signal
until it becomes displaced via competitive binding of cocaine, with incredibly fast
recovery of its fluorescence (i.e., seconds). To minimize the background signal and
obtain a high signal-to-noise ratio, we used a fixed concentration of 38-GC (2 μM)
to optimize the concentration of ATMND and thus obtained an optimized 38GC:ATMND ratio of 8:1 (Figure 8); under these conditions, we calculated that
99.3% dye–aptamer complexes contained only one ATMND molecule bound at
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the strong binding site, while the concentration of complexes containing two
ATMND molecules was sufficiently low as to be negligible (see modeling
calculations).

Figure 8. Effect of different concentrations of ATMND on fluorescence signal gain.
Maximum signal gain was achieved at an optimized molar ratio between the 38GC aptamer and ATMND of 8:1. [38-GC] = 2 µM, [cocaine] = 50 µM, with excitation
at 358 nm and emission at 405 nm.
3.4.1

Modeling data for binding of ATMND to 38-GC:

Two assumptions are required for the calculation
1. One DNA aptamer molecule can bind one or two ATMND molecules in its
hydrophobic pocket;
2. Two ATMND molecules can occupy the hydrophobic binding pocket
independently
In the presence of ATMND, a DNA aptamer molecule can bind a single ATMND
molecule strongly at site 1 to form complex 1 or it can bind one ATMND molecule
weakly at site 2 to form complex 2, establishing two equilibriums in the solution:
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Site 1 (strong binding):
1/Kd1
DNA + ATMND

Complex 1

(I)

Complex 2

(II)

Kd1

Site 2 (weak binding)
1/Kd2
DNA + ATMND

Kd2

There is also a possibility for complex 1 to bind a second ATMND molecule weakly
or for complex 2 to bind a second ATMND molecule strongly. Thus, another two
related equilibriums are formed independently:

Complex 1 + ATMND

1/Kd2
Kd2

Complex 3

(III)

Complex 3

(IV)

1/Kd1
Complex 2 + ATMND

Kd1

(Kd1 and Kd2 stand for the dissociation constant between the ATMND molecule and
the DNA aptamer at its strong binding site or its weak-binding site, respectively.)
The dissociation constant for reactions (I-IV) can then be defined in terms of the
equilibrium concentration of each component:
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[𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷][𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷]

(1)

[𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷][𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷]

(2)

[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1][𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷]

(3)

[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2][𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷]
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3]

(4)

𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑1 =
𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑2 =
𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑2 =
𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑1 =

[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1]
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2]
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3]

By using equation (1) to divide equation (2), we deduce equation (5):
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2]
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1]

=

𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑1

(5)

𝐾𝐾𝐾𝐾𝑑𝑑𝑑𝑑2

Equation (6) can be deduced from equations (2) and (3),

Thus,

[𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷][𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3]
=1
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2][𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1]

[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3] = [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2]

(6)

[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1]
[𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷]

ATMND is not completely consumed in the reaction due to the equilibrium;
therefore a comparison can be successfully made between the equilibrium
concentration of ATMND and DNA and their total concentration (denoted as
ATMNDT and DNAT)
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[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1]
[𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷]

<

𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑇𝑇𝑇𝑇

𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑇𝑇𝑇𝑇 − 𝐷𝐷𝐷𝐷𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑇𝑇𝑇𝑇

=

0.25 𝑢𝑢𝑢𝑢𝐴𝐴𝐴𝐴

2 𝑢𝑢𝑢𝑢𝐴𝐴𝐴𝐴 − 0.25 𝑢𝑢𝑢𝑢𝐴𝐴𝐴𝐴

=

1

(7)

7

Equation (6) can be recalculated using the solution from equation (7) to obtain the
comparison of the equilibrium concentration between complex 2 and complex 3:
1
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3] < [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2]
7

Based on ITC data, the values of dissociation constants (Kd1 and Kd2) of ATMND
to 38-GC are 0.016 uM and 2.6 uM, respectively. Thus, a relationship between the
concentration of the three complexes is established as follows:
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] = 162.5[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2] > 1137.5[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3]

Thus, the percentage of complex 1:
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1]

[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] + [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2] + [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 3]
=

1
1
>
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶 2] [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶 3]
1
1
1+
+
+
+
162.5 1187.5
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1] [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1]
[𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶 1]

= 99.3%

Since 99.3% of the ATMND-aptamer complex is complex 1 in which the aptamer
only bind one ATMND at the strong site, we have ignored the formation of complex
and complex 3 in the reaction.
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3.4.2

Mutation of binding pocket nucleotides

Our sensor is modeled on the understanding that both ATMND and cocaine
compete for the same aptamer, and we assume that the binding site of both ligands
is located within the hydrophobic three-way junction pocket. To confirm this
assumption, we examined the extent to which targeted nucleotide changes affects
ligand binding and target competition. We designed mutants of 38-GC in which we
introduced a nucleotide switch between T20 and C21 (38-GC-M1; Figure 9) or a
replacement of thymine at position 20 with an adenine (38-GC-M2; Figure 9).
Previous publications have determined that such mutations eliminate binding
affinity for cocaine. We tested these mutant aptamers in our competitive cocainebinding fluorescence assay and observed significantly reduced binding to both
ATMND and cocaine, with a high fluorescence background and a low cocainedisplaced fluorescence recovery (Figure 9). This poor ATMND binding and weak
cocaine displacement resulted in a signal gain of just 1.3 and 1.2 with 50 μM
cocaine for 38-GC-M1 and 38-GC-M2, respectively. This very weak binding affinity
of mutant aptamers to both ATMND and cocaine was also confirmed by ITC
(Figure 10). The enthalpy change in the binding interaction of both ATMND and
cocaine with the mutated aptamers was much smaller, suggesting inhibition of
hydrogen bonding. This is consistent with previous studies showing that mutations
to nucleotides that contribute to formation of this hydrophobic pocket, including the
unpaired T20 and C21, can profoundly alter the aptamer’s binding affinity for
cocaine.149
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Our mutation experiments indicate that ATMND binding is also heavily dependent
on C21 and T20. Nakatani et al.150,151 used

N NMR experiments to reveal that

15

1,8-naphthridine selectively binds to cytosine or thymine via a three-point hydrogen
bond152 and that the binding affinity of ATMND to various target nucleotides is as
follows: cytosine > thymine > adenine > guanine.66 Thus, it is likely that ATMND
binds either C21 or T20 within the three-way junction of the aptamer through a
three-point hydrogen bond.153,154 Additionally, we observed a large negative
enthalpy change in ITC experiments, which also indicates the formation of
hydrogen bonds between ATMND and the aptamer. We believe that ATMND forms
these hydrogen bonds and possibly cooperates with adjacent nucleotides via πstacking interaction to significantly quench its fluorescence (figure 11).153–156
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Figure 9. (A-D) Modifications of the 38-GT aptamer. Convert a GT base-pairing to
a GC base-pairing in stem 3 (B) further increases its ligand binding affinity,
whereas mutations in the binding pocket (C, D) reduce ligand affinity. (E) Mutations
to the unpaired bases in the hydrophobic binding pocket of 38-GC alter ATMND
binding and cocaine detection. Both the 38GC-M1 and 38-GC-M2 mutants
exhibited decreased quenching efficiency and cocaine-displaced signal gain. (F)
A fluorescence binding assay shows the differences in signal gain for these various
38-GT derivatives in the presence of 50 µM cocaine. Experimental conditions:
[DNA] = 2 µM, [ATMND] = 250 nM. Error bars represent the standard deviation of
three measurements.
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Figure 10. 38-GC-M1 and 38-GC-M2 demonstrated a very weak binding affinity
for ATMND and cocaine.
(A, B) ITC data showing heat generated from each injection and integrated heat
plot of (A) cocaine or (B) ATMND into the 38-GC-M1 aptamer solution. (C, D) ITC
data showing heat generated from each injection and integrated heat plot of (C)
cocaine or (D) ATMND into the 38-GC-M2 aptamer solution. Experimental
conditions: [38-GC-M1/M2] = 20 µM, [ATMND] = 500 µM and [cocaine] = 500 µM.
Binding experiments were performed in 10 mM Tris (pH 7.4) including 0.01 mM
MgCl2 and 5% DMSO at 25 °C.
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Figure 11. Binding of ATMND to the cocaine aptamer.
Mutational studies and isothermal titration calorimetry indicate that formation of the
three-way junction structure and the cytosine at position 20 are highly important
for binding of ATMND. Thus, we propose that ATMND possibly binds at this site
thru hydrogen bonding as it can be protonated in solution. ITC experiments exhibit
large enthalpy changes which suggest formation of such hydrogen bonds. Binding
of ATMND is essentially eliminated upon mutation of the C20 nucleotide,
suggesting a possible binding site for ATMND.
Our sensor is based on a simple, one-pot, one-step reaction that entails the simple
mixing of 38-GC, ATMND, and cocaine at room temperature and then exploiting
the rapid competition between cocaine and ATMND for limited aptamer binding
sites to quantitatively detect cocaine in samples. We observed that the signal gain
increased with cocaine concentration, reaching a saturated signal gain of 19 with
250 μM cocaine (Figure 12A), with a linear range of 0–8 μM (Figure 12A, inset).
The low background resulting from the high affinity interaction of 38-GC with
ATMND yields an excellent limit of detection (LOD). In a reaction with 2 μM 38-GC
and 250 nM ATMND, we achieved an LOD of 200 nM within 20 s, more than 50fold better than most existing aptamer-based systems59,63,64,142,148,157 and
comparable to sensitive assays that require enzymatic amplification (Table 2). The
LOD was calculated as S/N > 3, where the noise was a drug-free sample and the
minimum amount of sample was 3 times this amount.
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Figure 12. Sensitivity and specificity of the ATMND-based sensor in the reaction
buffer.
(A) Calibration curve shows a strong concentration-dependent response to
cocaine by 38-GC-ATMND. (B) Our sensor specifically responds to cocaine but
exhibits almost no response to its major metabolite benzoylecgonine.
Experimental conditions: [DNA] = 2 μM, [ATMND] = 250 nM. Error bars in plot A
represent the standard deviation of three measurements conducted at each
cocaine concentration.
Table 2. Comparison of aptamer-based sensors for cocaine detection

The 38-GC-ATMND complex offers a superior signal transduction mechanism for
immediate and specific cocaine detection with a robust signal gain. Since Cy7 has
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been used as a signal reporter in a previously reported cocaine-mediated aptamerbased assay,60 we compared the sensor performance of 38-GC with either Cy7 or
ATMND under optimized conditions and confirmed that 38-GC exhibits a much
better signal gain and sensitivity with ATMND. For example, our ATMND-based
“signal-on” sensor produces an approximate signal gain of 17 with only 1.5% of
relative standard deviation (RSD) in the presence of 50 μM cocaine (Figure 12A),
while the same cocaine concentration produces only a 35% signal decrease with
5% of RSD for the Cy7-based “signal-off” sensor (Figure 13).

Figure 13. Calibration curve for a 38-GC-Cy7-based sensor.
Experimental conditions: [38-GC] = 2 µM, [Cy7] = 7 µM. Error bars represent the
standard deviation of three measurements conducted at each cocaine
concentration. Relative sensor response in terms of percent change is shown,
because this is more reproducible than absolute absorbance values. The signal
gain is calculated as [(Abscocaine-Cy7 - Absbackground) / (AbsCy7 - Absbackground)] × 100%
where the background is derived from buffer and absorbance was measured at
760 nm.

58

Cocaine-binding aptamers generally exhibit good specificity in terms of
distinguishing cocaine from structurally similar major metabolites.57 We tested the
specificity of our assay with benzoylecgonine, which is the corresponding
carboxylic acid derivative of cocaine with an otherwise almost identical
structure.158,159 Relative to the signal gain of 17 obtained with 50 μM cocaine, we
did not detect a measurable signal change upon addition of 50 μM
benzoylecgonine and observed a signal gain of just 1.7 when we increased the
benzoylecgonine concentration to 1 mM (Figure 12B), which is consistent with the
good specificity observed with previous aptamer-based sensors (Table 2).
Additionally, we tested several other compounds for cross-reactivity with our
sensing method, including cocaethylene (biomarker of alcohol and cocaine
consumption), diphenhydramine (allergy medicine and cutting agent), cocaine
metabolites and cutting agents in street drugs. Several of these compounds do
not result in any measurable signal increase, however we did notice some crossreactivity

with

the

cocaine

metabolite

cocaethylene

and

the

drugs

diphenhydramine and promazine (Figure 14). Cross-reactivity with cocaethylene
would allow for detection of co-consumption of alcohol and cocaine while crossreactivity with over the counter drugs such as diphenhydramine might be
problematic in instances where they are being consumed as medicine or are
present as cutting agents in street samples. Wang et al. detailed a method that
can be used to increase the specificity for the same cross-reactive molecules by
utilizing an enzyme-based detection method.110
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Figure 14. Cross-reactivity of the ATMND-sensor for several compounds of
interest in cocaine measurements.
Cocaethyelene metabolite was found to bind to the aptamer and result in increased
fluorescence as well as diphenhydramine (allergy medicine) and promazine
(antipsychotic). The cutting agent scopolamine does not result in any interference.
The average concentration of cocaine in different body fluids within 24 h after
ingestion is typically greatest in the urine (milligrams per liter), with lower
concentrations found in saliva and serum, respectively.56 We explored the
practicality of our assay for performing cocaine detection in different body fluids
collected from healthy donors. We first tested our assay with 250 μM cocaine
spiked into various dilutions of urine, saliva, or serum (Figure 15) samples. We
observed that the signal gain increased in inverse proportion to the biofluid
concentration, with a maximum signal gain of 8.2, 9.6, and 5.6 for 2.5% urine,
saliva, and serum, respectively. Human urine normally contains very small
amounts of protein (<0.14 mg/mL)160 and a large number of fluorescent
metabolites.161,162 We observed that urine samples indeed generated a strong
background fluorescence at 400–550 nm (Figures 16 and 17) and metabolites
such as pterins, flavins, porphyrins, and 4-pyridoxic acid may be contributing to
this fluorescence.163 Although the urine matrix exhibited a high background
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fluorescence, we still achieved successful detection of cocaine. We observed that
the signal gain increased with increasing cocaine concentrations, with an LOD of
460 nM cocaine in 2.5% urine (Figure 18A).

Figure 15. Successful detection of cocaine spiked into different dilutions of urine,
saliva and serum with 38-GCATMND.
Signal gain decreases with increasing concentrations of urine. Experimental
conditions: [38-GC] = 2 µM, [ATMND] = 250 nM and [cocaine] = 250 µM, with
excitation at 358 nm and emission at 405 nm. Error bars represent the standard
deviation of three measurements. The signal gain is calculated as (Fcocaine-ATMND Fbackground) / (FATMND - Fbackground) where the background is derived from the biofluid
sample.

Figure 16. 5% urine and serum samples emit fluorescence within the wavelength
range from 375 nm to 600 nm when excited at 358 nm.
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Figure 17. Fluorescence intensities for different concentrations of various
biofluids.
Serum and urine both generate high fluorescence, which increases with the
increase of concentration. In contrast, saliva emits no fluorescence. Excitation
wavelength: 358 nm, and emission wavelength: 405 nm.

Figure 18. Calibration curves for ATMND-38-GC-displaced cocaine detection in
biological samples.
We observed a strong concentration-dependent response to cocaine in (A) 2.5%
urine and in (B) 5% saliva. Experimental conditions: [DNA] = 2 μM, [ATMND] = 250
nM. Error bars represent the standard deviation of three measurements conducted
at each cocaine concentration.
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Serum samples generate weak background fluorescence (Figures 16 and 17).
However, since serum contains ∼67 mg/mL protein,164 which might bind ATMND

molecules within hydrophobic patches and thereby quench its fluorescence
(Figure 19), we expected these samples to be significantly challenging to work
with. Even though serum samples demonstrated considerable ATMND quenching
at 405 nm (Figure 19), we were still able to detect cocaine in 2.5% serum with a
detection limit of 900 nM (Figure 20). Saliva is a cleaner matrix with no background
fluorescence (Figure 17), containing only ∼1.6 mg/mL proteins,165 and we were

thus able to use 5% saliva to achieve cocaine detection and establish a calibration
curve with an LOD of 520 nM (Figure 18B). Based on these findings, we calculated
detection limits of 10.4, 18.4, and 36 μM in undiluted saliva, urine, and serum,
respectively. These experiments successfully demonstrate the feasibility of using
our sensor to detect cocaine in body fluids.

Figure 19. Fluorescence intensities of ATMND in different concentrations of saliva
and serum.
The fluorescence of ATMND was quenched by higher concentrations of saliva and
serum. Excitation wavelength: 358 nm, and emission wavelength: 405 nm.
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Figure 20. Calibration curves for cocaine detection with ATMND-38-GC in 2.5%
serum.
(A) Concentration–dependent response of signal gain to cocaine concentration.
(B) Linear relationship between signal gain and cocaine concentration within the
range from 0 to 8 µM. Experimental conditions: [38-GC] = 2 µM, [ATMND] = 250
nM, with excitation at 358 nm and emission at 405 nm. Error bars represent the
standard deviation of three measurements conducted at each cocaine
concentration.
3.4.3

Detection in alcoholic and soft drinks

We further used the ATMND-cocaine test to measure cocaine in drinks such as
beer and soda. Detection was performed in 10% diluted solutions with spiked
cocaine (250 uM). Detection in several soft drinks proved difficult because of
intense background fluorescence, however detection was still possible in drinks
such as tea, Coca-Cola and soda (Figure 21). Detection of spike cocaine was also
tested in alcoholic drinks. Several alcoholic drinks resulted in unreliable detection
because of high background fluorescence even in the absence of cocaine.
Detection was still possible in several diluted alcoholic drinks (Figure 22). The
outlined method thus can successfully detect cocaine in spiked drinks, however
care should be taken to examine the background fluorescence of the matrix.
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Figure 21. Detection of cocaine in spiked soft drinks.
(A) fluorescence intensity of ATMND in soda solution. Addition of cocaine results
in a significant fluorescence increase because of the spiked cocaine in the solution.
(B) Different soft drinks were tested with only Gatorade resulting in unreliable
detection of cocaine. [DNA] = 2 uM, [ATMND] = 250 nM, [COC] = 250 uM, Ex: 358
nm, Em: 405 nm.

Figure 22. Detection of cocaine in alcoholic drinks.
Several drinks were diluted to 10% and spiked with cocaine. Detection was
performed with the ATMND-method resulting in correct detection for several
drinks. However, several drinks exhibit intense fluorescence that results in
unreliable results. Care should be taken to examine the fluorescence signature in
a case by case basis. [DNA] = 2 uM, [ATMND] = 250 nM, [COC] = 250 uM, Ex:
358 nm, Em: 405 nm.
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3.5 Conclusion
We have demonstrated the rapid, sensitive, and specific detection of cocaine
based on competitive aptamer binding between the cocaine target and the ATMND
fluorescent signal reporter. Our 38-GC aptamer is derived from the previously
reported MNS-4.1 aptamer and incorporates additional complementary base pairs
at multiple sites that stabilize aptamer folding and thereby increase binding affinity
to both ligands and reduce background fluorescence. ATMND fluorescence is
significantly quenched upon binding to 38-GC. In the presence of cocaine,
however, ATMND is displaced from the dye–aptamer complex, generating an
intense fluorescence signal. We confirmed the competitive binding of the two
ligands to the 38-GC and demonstrated that targeted mutagenesis clearly affects
sensor performance.
Our assay is remarkably simple, fast, and specific. Detection is performed in a
single tube containing the 38-GC-ATMND complex and the sample of interest. The
assay is label-free, and detection only requires 20 s at room temperature to
achieve a linear range of 0–8 μM with an LOD of 200 nM in buffer, about 50-fold
lower than assays based on target-induced conformational change.11,57,59,64,140–144
More importantly, our assay can achieve successful cocaine detection in body
fluids. We observed that the signal gain increased with increasing cocaine
concentrations, obtaining LODs of 10.4, 18.4, and 36 μM in undiluted saliva, urine,
and serum samples, respectively. After a dose of 100 mg, it is reported that cocaine
concentration is around 2 mg/L in urine, about 3 times lower than the LOD of our
sensor.166 Thus, a major limitation of the current assay is the interference by auto66

fluorescence of the biological sample which limits the sensitivity. This could be
possibly overcome by utilizing a dye outside the 358/405 nm window. We
anticipate that the well-established SELEX technique should likewise make it
possible to derive similar target-ligand displacement sensors that exhibit equally
high specificity and affinity for other small molecules. This approach therefore
potentially offers a general framework for performing rapid and specific highthroughput on-site drug testing.
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CHAPTER 4
Engineering an adenosine-specific aptamer and electrochemical detection
in undiluted serum
A simple and specific method for the detection of adenosine is becoming
increasingly valuable as knowledge of its modulatory function in physiology and
pathophysiology are explicitly understood. Unfortunately, the previously reported
Adenosine aptamer (ATP-27) cannot be utilized to measure adenosine
concentration because of its inherent cross-reactivity to adenosine phosphate
derivatives such as adenosine triphosphate (ATP) and adenosine diphosphate
(ADP), which share a common core structure (ribose and adenine) and are copresent in biological samples. Through rational engineering of the aptamer’s
sequence, we designed and characterized a new highly specific adenosinebinding aptamer which differs from ATP-27 by a single nucleotide and exhibits
reduced cross-reactivity for ATP, ADP and adenosine monophosphate (AMP). The
reduced cross-reactivity can be attributed to steric hindrance for negatively
charged phosphate derivatives in the binding pocket, resulting in decreasing
affinity as the negative phosphate charge increases, yet neutral adenosine is not
affected. The aptamer can be modified and incorporated into an electrochemical
aptamer-based (E-AB) platform for sensitive and specific detection of adenosine
in buffer and undiluted serum. Sensitivity in serum is at least 40 times higher
compared to other aptamer-based sensors but with specificity for adenosine
against ATP, ADP and AMP that has not been previously reported in aptamerbased serum measurements.
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4.1 Introduction
Adenosine is an endogenous regulatory molecule with signaling function in diverse
systems including immune and inflammation response, neuro-modulation,
coronary blood flow and cancer pathogenesis.73,84,167 Membrane equilibration
channels transport adenosine to the outside of the cell, however the bulk of extracellular adenosine is produced by metabolism of nucleotides (ATP, ADP and AMP)
by membrane-bound ecto-enzymes (i.e., CD39 and CD73).123 The enzymes work
in concert to transform ATP to adenosine, first by transformation of ATP to AMP
by CD39 followed by metabolism of AMP to adenosine by CD73.85 Intracellularly,
adenosine homeostasis is regulated by enzymes such as adenosine deaminase
(ADA: transforms adenosine to Inosine) and adenosine kinase (ADK: transforms
adenosine to AMP).168 Extracellular adenosine can regulate physiological
functions by binding to and activating four distinct adenosine receptors (A1, A2a,
A2b and A3) expressed in nearly all cell types.75 Physiological concentration of
extracellular adenosine (30-300 nM) can effect regulatory functions with the highaffinity receptors (A1, A2a, and A3) but not with the low affinity receptor A2b.169
Activation of the A2b receptor by adenosine requires concentrations 100 - 1,000
times above physiological levels (>10 uM), which are only observed in pathological
states such as hypoxia, tissue damage, cell-stress and cancer.74,76,170 Accordingly,
adenosine measurements have been used to diagnose diseases, monitor
therapeutic efficacy, understand the role of purinergic enzymes and adenosine
receptors in pathophysiology, and to indirectly quantify adenosine regulatory
enzymes and profile potential inhibitors of these enzymes.77,78,171–173 For example,
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Corcuilo et al. proved that mice lacking the adenosine receptor A2a or the enzyme
CD73 (transforms AMP to adenosine), spontaneously develop osteoarthritis with
replacement of adenosine by injection preventing development of osteoarthritis in
rats.174 Taniai et al. demonstrated higher concentrations of adenosine in the urine
of patients suffering from metabolic disease or severe respiratory failure.171 Bimal
et al. demonstrated elevated plasma adenosine levels during active visceral
leishmaniasis (VL) disease and return to basal adenosine levels after successful
treatment.172 An important aspect of these studies was utilization of a reliable
method for adenosine measurements. Currently available methods include microdialysis, HPLC, enzyme-linked spectroscopic assays, and chromatography-MS
based methods.77,80,82,175 These methods require complex procedures, expensive
instruments, lengthy sample processing, and have limited temporal resolution.
Chen et al. argued that a current challenge in therapeutic targeting of adenosine
receptors is the unavailability of simple and direct adenosine sensors.75
Various groups have attempted to develop simple sensing methods to measure
adenosine concentrations with high specificity. Ahn et al. developed a chemical
method

that

indirectly

measured

adenosylhomocysteine-hydrolase

to

adenosine

transform

by

employing

s-adenosylhomocysteine

sto

homocysteine and adenosine. Homocysteine results in fluorescence quenching of
a silver nanocluster and exogenous adenosine is indirectly measured as it inhibits
the

enzymatic

reaction

of

s-adenosylhomocysteine-hydrolase

preventing

production of the homocysteine which regulates the fluorescence output. The
method showed great specificity against ATP and ADP in 5% diluted complex
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samples, however the method was not tested in undiluted serum.176 Additionally,
the method requires exogenous reagents and time-consuming enzymatic
reactions which limit the temporal resolution.177 Biovision has a commercially
available fluorescence kit for indirect detection of adenosine in serum and urine.
Biovision’s method relies on transformation of adenosine by adenosine deaminase
to inosine and a downstream enzymatic transformation (not publicly available) of
the resulting product for fluorescence detection.178 While highly sensitive, the
method is not highly specific, with intense background interference from
endogenous inosine and xanthine, molecules which are commonly present in
biological samples.179 Other methods have also been developed based on enzyme
recognition of adenosine and cascading catabolism of the target molecule to
eventually produce hydrogen peroxide, which can be measured using
electrochemistry or spectroscopy.81,180 Specifically for electrochemical sensors,
enzyme immobilized electrodes require specialized and careful preparation and
are inherently sensitive to interfering electroactive molecules in the sample solution
because of the interrogating potential of +500 mV required for oxidation of
hydrogen peroxide which also oxidizes molecules endogenously present in
biological samples such as ascorbate.81,180 Specific detection of adenosine is also
affected by inosine concentration (adenosine metabolite) which must be
subtracted by a separate inosine reference sensor. While these methods are more
convenient than conventional methods (e.g. HPLC), they do not measure
adenosine directly, thus they suffer from poor specificity against matrix interferents.

71

Aptamer-based sensors are increasingly gaining popularity because of their high
and tunable specificity, adaptability to highly selective sensing mechanisms and
high

sensitivity.9,144,181,182 Aptamers

are

oligonucleotide-based

recognition

molecules that can bind specific analytes such as small molecules and
proteins.38,39 An analyte of interest, such as adenosine, is incubated with a large
population of random and distinct oligonucleotide sequences of fixed length,
termed a ‘library’. Distinct sequences in the library that strongly bind the analyte
are continuously amplified (i.e., enriched) and non-binding sequences are
discarded; this artificial evolution process (termed SELEX) is repeated until a
unique binding sequence is isolated.39 The specificity of the isolated sequence can
be controlled by appropriate design of the incubation and separation steps; thus
aptamers can be made to be highly specific for a given molecule or cross-reactive
for a family of molecules, depending on the selection conditions.139,183
Interestingly, the previously isolated ATP-binding aptamer (herein termed ATP-27)
is highly cross-reactive with ATP, ADP, AMP, and adenosine with little interaction
with the mono/di/tri-phosphate portion of the adenosine molecule.47,184–187 The full
molecular structures are presented in figure 1. Biological fluids contain mixtures of
ATP, ADP, AMP and adenosine because of the sensitive homeostasis mechanism
of cell energy consumption and signaling.75 Indeed, ATP is present at higher
concentrations intracellularly (mM vs nM) and extracellularly as compared to
adenosine, thus utilization of the current ATP-27 aptamer for specific sensing of
adenosine is not possible.73,76 Unfortunately, most aptamer-based sensors for
adenosine have focused on improving the sensitivity or the specificity against
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matrix interferences, but have largely ignored the cross-reactivity problem that
prohibits the use of the current aptamer for measurements in biological
fluids.48,79,188 For example, time-resolved spectroscopy and flow cytometry
aptamer-methods have achieved detection of adenosine in complex serum
samples. However, these methods were not able to overcome the specificity
problem of the ATP-27 aptamer and additionally sacrificed analytical performance
with up to 10-20 times reduced binding affinity for adenosine, limiting their utility
for clinical applications (sensitivity: 60-200 uM).46,189 Several groups have
attempted to isolate more specific aptamers ATP, ADP and adenosine.86,190,191 For
example, an ATP specific RNA aptamer was isolated however this aptamer
interacts strongly with the phosphate backbone resulting in unwanted crossreactivity with guanosine triphosphate (GTP).191 Stojanovic et al. reported a unique
adenosine binding aptamer that can bind adenosine and cyclic-AMP but does not
bind any other adenosine-phosphate derivatives.86 Unfortunately, apart from the
selection publication there is no additional information available about this
aptamer, characterization of its structure or its application in complex sample
measurements. The current limitation for a functional aptamer-based sensor for
adenosine detection is thus the inability to design a sensing platform that can
simultaneously overcome the issues of specificity against similar molecules (i.e.,
cross-reactivity), specificity against matrix interferents and reach an appropriate
level of sensitivity (e.g., micromolar).
To simultaneously overcome these challenges, an adenosine-specific aptamer
must be developed and coupled to a highly selective and highly sensitive signaling
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mechanism. Through rational sequence engineering of the original ATP-27
aptamer, I discovered a new oligonucleotide sequence that can specifically bind to
adenosine and has reduced interactions with ATP, ADP and AMP. Additionally,
the new adenosine-specific aptamer has a similar stem-loop structure as the
original aptamer and it can be easily adapted to various signaling methods
including electrochemistry. Electrochemical aptamer-based sensors (E-AB) can be
utilized directly in complex samples (e.g., undiluted serum) with target-dependent
response that is largely insensitive to interfering molecules in the matrix but whose
cross-reactivity is characterized by the employed aptamer.93,192–194 The aptamer
modulates the measured current by changing its conformation (i.e., secondary
structure) upon target binding, which changes the distance and mobility of a
covalently-attached redox molecule to the electrode surface.92,97,195,196 Signaling
only occurs through specific target-induced changes in the aptamer’s secondary
structure and is therefore mostly irresponsive to non-binding molecules and
adsorption of contaminants to the electrode surface. Additionally, the scarcity of
electroactive molecules in complex samples such as blood ensures interferencefree detection, as opposed to optical-based sensors which suffer from significant
interference from non-target absorbing and fluorescent molecules.176,182 Our
method exhibits high specificity against similar molecules (e.g., vs. ATP, ADP and
AMP), high specificity against matrix interferents even in undiluted serum and high
sensitivity, simultaneously overcoming the limitations of current aptamer-based
sensors for adenosine. I discuss a probable explanation for the enhanced
specificity of the new adenosine-specific aptamer, its significance for future sensor
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design and for the first time report an aptamer-based method for specific
adenosine detection in undiluted serum, as evidence of its possible application in
the medical and research fields.
4.2 Experimental Section
Reagents
Adenosine, adenosine triphosphate (ATP), adenosine diphosphate (ADP),
adenosine monophosphate (AMP) and guanosine triphosphate (GTP) were
purchased from Sigma and dissolved to 10 - 50 mM concentration in deionized
water (DI) and neutralized with sodium hydroxide. Approximate concentrations
were obtained from absorption measurements at 259 nm and utilization of the
appropriate extinction coefficient. Exonuclease I (Exo I) and Exonuclease III (Exo
III) were purchased from New England Biolabs (NEB) and stored at -20 °C in 5 uL
aliquots of stock solution of 100 U/µL. Oligonucleotide DNA aptamers were
acquired

from

IDT

DNA

technologies

with

high-performance

liquid

chromatography (HPLC) purification in most cases except for isothermal titration
calorimetry and circular dichroism experiments, which used standard desalted
DNA. Methylene-blue (MB) modified DNA was purchased from Biosearch with
HPLC purification. All DNA was dissolved using nuclease free water; the
approximate concentration was measured at 260 nm with the corresponding
extinction coefficient of each DNA sequence and stored at -30 °C until used. The
DNA sequences utilized are listed in the following table:
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Table 3. Aptamer sequences, modifications and substitutions.

4.2.1 Polyacrylamide gel electrophoresis (PAGE)
Denaturing polyacrylamide gel electrophoresis was utilized to determine the length
of the DNA products of enzyme reactions. In all cases, 15% gels were used to
provide optimal resolution and band separation. Gel preparation consisted of
mixing 9.4 mL of 40% acrylamide solution, 5 mL of 5X Tris-Borate-EDTA (TBE),
2.6 mL of deionized water (DI), 100 µL of freshly prepared 10% ammonium
persulfate (APS) (w/v), and 10 µL of tetramethylethylenediamine (TEMED). Gels
were left to polymerize for 2 hours before pre-running at 450V for 30 minutes with
0.5X TBE running buffer. Samples were loaded at 3 µL per well (20 wells per gel).
The running conditions were 30 mins. at 100V and 2 hours at 400V. The sample
bands were compared to a DNA control without enzyme treatment to approximate
the concentration of the resulting product. A marker lane was used to estimate the
product nucleotide count.
4.2.2

Enzyme reactions

A DNA stock solution of 50 µM was heated to 95 °C and then cooled on ice for 5
minutes. The DNA was mixed in buffer solution (10 mM Bis-tris-propane, 1 mM
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MgCl2, 1x Bovine Serum Albumin (BSA) at pH 8.5) and the appropriate target was
added (e.g., adenosine). The target and aptamer were incubated at 23 °C for 30
minutes in a heating plate. Exonuclease I and exonuclease III were diluted at
varying concentrations with 1X BSA buffer (10 mM BTP, 1x BSA at pH 8.5) unless
otherwise indicated and were then added to the aptamer-target mixture. The
reactions were performed at 23 °C in 200 µL PCR tubes for the time indicated. The
reaction was stopped by mixing 5 µL of the reaction mixture with 10 µL of stop mix
loading buffer (formamide and EDTA).
4.2.3

Isothermal Titration Calorimetry (ITC)

A Malvern ITC200 was used for the following experiments. The cell was loaded
with the appropriate DNA sequence and the syringe was loaded with the small
molecule ligand (e.g., adenosine). The concentration of DNA in the cell was varied
between 15 - 30 µM to achieve sufficient heat in each injection as well as saturation
and quality fitting curves. The syringe concentration was restricted to between 450
- 600 µM of each small molecule attributable to significant heat of dilution being
observed at higher concentrations. The heat of dilution from a ligand to buffer run
was subtracted from sample runs. A general experiment consisted of a 0.4 µL
purge injection, which was removed prior to data analysis, and 18 additional 2 µL
injections. In cases where saturation was not achieved in a single run, the syringe
was reloaded with ligand and a second run was performed. The data were then
aggregated onto a single file for fitting. It is noted that the DNA used for these
experiments was only desalted with no other purification. Accordingly, an
estimated concentration was utilized for the data fitting, with a probable full-length
77

oligo of 80% in the overall oligo mixture according to the manufacturer, IDT DNA.
To fit the data, we used a sequential binding model based on previous literature
which indicate a small factor of cooperativity observed in the original ATP aptamer
which has been characterized to have two distinct, binding sites for ATP.197,198
4.2.4

Circular Dichroism (CD)

A Jasco J-815 CD was used for these experiments. The DNA concentration was
2.5 µM and the target molecule concentration was 25 µM. The target molecule
concentration was restricted because of significant absorption of adenosine
containing compounds at 259 nm. The aptamer solution and aptamer-target
solutions were prepared separately and incubated at 23 °C for 30 minutes to
maintain the same conditions as those used for enzyme reaction experiments. We
used standard sensitivity of the instrument and scanned the spectra form 300 nm
to 215 nm with a data pitch of 0.1 nm at 50 nm/min. The given results are the
average of 5 scans. We monitored the scans with 3 channels: CD, HT and
Absorbance. The background from the absorption of buffer and small molecule
target in buffer were subtracted from aptamer-target mixtures.
4.2.5

Aptamer immobilization to gold electrodes

The gold electrodes were first polished in alumina slurry for 5 minutes and
subsequently sonicated in deionized water and absolute ethanol for 5 minutes
each. The electrodes were then electrochemically cleaned following the protocol
by Xiao et al.94 First, an electrochemical reduction/oxidation cycle was performed
in 0.5M sodium hydroxide from -0.35V to -1.35V and rescanned 1,000 times. A
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subsequent round of oxidation/reduction steps were performed in 0.5M sulfuric
acid (H2SO4) and a final round was performed in 0.01M potassium chloride
(KCl/0.1M H2SO4). The working area of the electrode was determined in 0.05M
H2SO4 by calculation of the reduction peak of gold oxide.199 The electrodes
generally displayed a roughness ~1.1. Thiol-modified DNA was incubated with 10
mM tris(2-carboxyethyl)phosphine (TCEP) to reduce the disulfide bond. The
reactive thiol DNA was then diluted to 645 nM in 1x phosphate buffered saline
(PBS) buffer. Aliquots of 200 µL of the DNA mixture were incubated with the
cleaned electrodes for a period of 4.5 hours in the dark at room temperature. The
modified electrodes were then backfilled with 3 mM 6-mercapto-1-hexanol (MCH),
1 mM MCH and 1 mM dithiothreitol (DTT) or 1.5 mM DTT for 3 hours to obtain
stable monolayers of modified aptamers.
4.2.6

Electrochemical measurements

A CHI 760 bi-potentiostat was used for all measurements. A Ag/AgCl electrode
was used as the reference electrode and a platinum wire was used as the counter
electrode in a three-electrode set up. Square wave voltammetry (SWV) was
employed to monitor the current as the potential was scanned from -0.1V to -0.5V
in 10 mM Bis-tris-propane, 50 mM NaCl buffer at pH 8.5. The frequency was set
between 5 - 300 hertz for optimization and 100 Hz. was ultimately used as the
optimal value. The amplitude was optimized to 25 mV and the scan rate was 1 mV.
The signal gain was calculated as the difference in peak current in the presence
and absence of target divided by the target-free peak current.
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Calibration curves were collected by titrating increasing concentrations of target
and final graphs were obtained from the average signal from at least 4 different
electrodes in separate solutions. DNA surface coverage was measured using a
previously reported protocol by Steel et al.200 Briefly, the modified electrodes were
incubated in tris buffer (pH 7.4) for 30 minutes prior to measurements. A small cell
was filled with the same buffer and degassed using argon for 10 minutes prior to
measurements. The electrodes were then immersed in the degassed buffer
solution while keeping the purging gas on. Chrono-coulometry was employed to
measure the absorption of ruthenium (III) hexamine and correspondingly calculate
the concentration of DNA molecules adsorbed onto the gold electrode surface as
described elsewhere.200
4.3 Results and discussion
4.3.1

Cross-reactivity of the original ATP-binding aptamer

Many publications have employed the 27-nt ATP-binding aptamer (herein termed
ATP-27) to develop different, highly sensitive sensors for ATP, ADP and adenosine
that can work in various samples matrices.184,201–203 However, in these
publications, the inherent cross-reactivity of the ATP-27 aptamer for ATP, ADP,
AMP and adenosine has been largely ignored or was inconsequential to the
presented topic. I utilized the enzyme exonuclease III to probe the binding affinity
of the various adenosine targets to the original cross-reactive ATP-27 aptamer.
Exonuclease III has been recently reported to be inhibited by formation of aptamertarget complexes, generally 4-nt away from the presumed binding site.110 Thus,
aptamer-target binding could be observed by gel electrophoresis of the enzymatic
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reaction products. A binding aptamer would produce bright bands corresponding
to enzymatic inhibition and non-binding sequences would display no product bands
as the enzyme would completely degrade the aptamer structure (fig. 23a). The
exonuclease III system requires aptamers with long stabilizing stems, thus the
original ATP-binding aptamer (ATP-27) was extended by three additional basepairs and termed ATP-33. Exonuclease III was heavily inhibited in the presence of
binding targets, including ATP, ADP, AMP, and adenosine with retained products
30-nt long and with concentrations of 833, 810, 276 and 548 nM, respectively (fig.
23c). The retained product concentrations were calculated by comparison against
the control band, which maintained a constant and known concentration. In the
absence of target, exonuclease III displayed full activity and completely degraded
the aptamer structure. Similar binding cross-reactivity of the ATP-27 aptamer has
been reported with a variety of detection methods.185–187,189 A non-binding mutant
sequence (ATP-33m) was utilized as a control with a single point mutation that
inhibits binding to confirm that inhibition was indeed an effect of specific target
binding and not due to enzymatic inhibition by the target itself.47 The ATP-33m
non-binding sequence did not result in inhibition regardless of the presence or
absence of target, which indicated that the target itself does not inhibit the enzyme
(Fig. 23b).

81

Figure 23. Specific target binding inhibited exonuclease III digestion of the
aptamer 4-nt away from the presumed binding site.
(top) structure of adenosine, ATP, ADP, and AMP at pH 8.5. (a) The original ATP27 aptamer was extended by addition of 3 base-pairs to the stabilizing stem and
the extended aptamer was termed ATP-33. Specific target binding inhibits
exonuclease III digestion, while in the absence of target the enzyme can digest the
aptamer. (b) Exonuclease III digestion products with the ATP-33 binding aptamer
have an estimated length of 30-nt. Only the targets which bind can inhibit the
enzyme. A mutant non-binding aptamer (ATP-33m) was used to confirm the
binding-induced inhibition of exonuclease III. None of the targets inhibited
exonuclease III. (c) The band intensity was converted to a concentration value by
comparing with the control band of constant and known concentration. The
binding-induced inhibition resulted in DNA inhibition with products of 833, 810, 276
and 548 nM for ATP, ADP, AMP and adenosine, respectively.
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4.3.2

Engineering of an adenosine-specific aptamer

My goal was to improve the adenosine-specificity of the ATP-27 aptamer through
rational sequence engineering, specifically via substitution of various nucleotides
in the target-binding domain of the aptamer. Li et al. previously noted that the ATP27 cross-reactive aptamer exhibited strong binding affinity to ATP and ADP, but
reduced binding affinity for AMP. The decreased binding affinity to AMP was
explained by the higher negative charge on the α-phosphate of AMP (-2) as
opposed to (-1) for ATP and ADP. The authors argued that the α-phosphate might
have close contact and interaction with the aptamer structure, thus the increased
negative charge of the AMP α-phosphate inhibited binding.83 We hypothesized that
rational mutation of the nucleotides near the binding site would modulate the
specificity of the aptamer for the various adenosine phosphate derivatives because
of their varying size and charge (molecular structures and charge displayed in
figure 23). Multiple nucleotides in the sequence were mutated, added or removed
and screened for target affinity via the exonuclease III inhibition system (fig. 24a).
Through rational mutation of the original ATP-27 aptamer sequence, we
discovered that a single nucleotide modification of an adenine at position 23
(counting from the 5’ end) to a thymine inhibits binding of negatively charged
adenosine derivatives (e.g., ATP, ADP, and AMP) but maintains affinity for neutral
adenosine (Fig. 24b). Binding of adenosine to the new adenosine-specific aptamer
(termed Ade-33) resulted in retention of 650 nM of product while all other
phosphate derivatives were almost fully digested (fig. 24c). A guided single-point
mutation was introduced to the Ade-33 aptamer to obtain a non-binding control
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sequence termed Ade-33m.47 The non-binding Ade-33m was utilized to confirm
that enzymatic inhibition was a result of specific target-binding. Complete digestion
occurred in the presence of all targets, further confirming the specificity of the new
aptamer for adenosine (Fig. 24b and c).

Figure 24. Exonuclease III screening test of engineered sequences and
identification of an adenosine-specific aptamer termed Ade-33.
(a) Structures of the original cross-reactive ATP-33 aptamer and the new
adenosine specific Ade-33 aptamer; A single nucleotide mutation at position 23
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(counting from the 5’ end) of A to T can modulate the specificity of the aptamer for
specific binding of adenosine. (b) Gel electrophoresis results of exonuclease III
reaction with a binding competent Ade-33 aptamer and a mutated non-binding
adenosine-specific aptamer (Ade-33m). (c) Concentration measurements of
retained product after enzymatic reaction. Binding of adenosine retains over 650
nM of DNA product, while all other targets are almost completely digested. The
mutated aptamer sequence is digested with all targets.
4.3.3

Addition of Exonuclease I to remove background fragments

Binding of the new adenosine specific aptamer can inhibit exonuclease III digestion
but several aptamer fragments are still observed even in the absence of target or
in experiments with a non-binding mutant. These short bands are single-stranded
fragments without base-pairing complementary and are poor substrates for
exonuclease III. I utilized the enzyme exonuclease I, which is highly specific for
digestion of single-stranded DNA from the 3’ end of the DNA sequence, to remove
the background shorter fragments. A fixed concentration of exonuclease III was
utilized to initially digest the parent aptamer along with increasing concentrations
of exonuclease I to determine the concentration required to digest the remaining
non-binding fragments. Addition of 3 units of exonuclease I was sufficient to
remove the single-stranded DNA byproducts yet retain most of the aptamer-target
complex product with nearly 450 nM retained (fig. 25b). Interestingly, increasing
concentrations of exonuclease I led to digestion of the 30-nt long aptamer-target
complex, suggesting that the initial exonuclease III inhibition product is in a
sensitive equilibrium between single- and double-stranded DNA conformations
(fig. 25c). Next, the exonuclease I concentration was held constant and the
exonuclease III concentration was varied to determine the minimum amount of
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exonuclease III required to obtain the binding inhibition product. As the
exonuclease III concentration is reduced, a different binding product is observed
(fig. 26). From these results, it appears that exonuclease III can recognize two
different aptamer fragments that can undergo structure-switching upon target
binding, with lengths of 30- and 29-nt (thus termed Ade-30 and Ade-29).
Exonuclease I is inhibited only in the presence of target because of formation of
double-stranded DNA upon target binding (fig. 26).

Figure 25. Addition of exonuclease I to remove single-stranded DNA fragments
leftover from exonuclease III reaction.
(a) Exonuclease III can digest the structure in the absence of binding target up to
a point where the structure becomes highly flexible single-stranded DNA, which is
a poor substrate for exonuclease III. Exonuclease I is highly specific for such
single-stranded DNA structures, allowing for digestion of the leftover fragments.
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(b) Gel electrophoresis results of increasing concentrations of exonuclease I at a
fixed constant exonuclease III concentration. Exonuclease I can digest the leftover
single-stranded DNA fragments, with 3 U being sufficient to easily identify the
aptamer-target complex. (c) Graphical representation of the band intensity as
converted into concentration by comparison with a control band of known and
constant concentration.

Figure 26. Exonuclease III can identify multiple aptamer fragments with apparent
structure-switching functionality.
In the absence of exonuclease III, exonuclease I does not digest the extended
Ade-33 structure as it is double-stranded structure. Upon digestion of exonuclease
III, two different binding fragments are produced which appear to undergo
structure-switching upon target-binding as they are not digested by exonuclease I,
unlike samples without target-binding which are readily digested by exonuclease
I.
4.3.4

Implications of magnesium concentration on Ade-33 specificity

ATP, ADP and AMP molecules binding to the adenosine-specific aptamer
sequence appear more susceptible to steric interactions from the substituted
thymine at position 23. We performed the enzyme reactions with the Ade-33
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sequence at various magnesium concentrations to test whether magnesium
affects binding between the thymine residue at position 23 and the phosphate
containing adenosine molecules. At high magnesium concentrations (> 5 mM), the
retention of Ade-33 products for adenosine and ADP was <250 nM while at low
magnesium concentrations (<5 mM) adenosine binding dominated and binding for
ADP was severely reduced with retained products of 500 nM for adenosine and
none for ADP (fig. 27). We conducted the same test for the original cross-reactive
ATP-33 aptamer and observed enzyme inhibition with ADP even at magnesium
concentrations as low as 0.25 mM (Fig. 27). Braun et al. previously demonstrated
a similar effect of ATP binding to the cross-reactive ATP-27 aptamer at low
magnesium concentrations.204 These results suggest that substitution of thymine
at position 23 results in steric hindrance with the negatively charged phosphate
groups of ATP, ADP and AMP. Thus, the Ade-33 aptamer was highly specific for
adenosine at magnesium concentrations below 5 mM. At a concentration of 1 mM
magnesium, the ADP retained product is 600 nM when bound to ATP-33 but no
product is retained when incubated with the Ade-33 aptamer (fig. 27). Magnesium
concentration above 5 mM appears to be sufficient to attenuate the steric
hindrance and stabilize binding of the negatively charged phosphate derivatives
with the Ade-33 aptamer.205,206 A corresponding effect was previously observed by
Szostak et al. who noted loss of ATP binding to an RNA aptamer in the absence
of magnesium and an increase in specificity for ATP in the presence of increasing
magnesium concentration.191 The authors proposed a role for magnesium where
it functions as a bridging ion between their RNA aptamer structure and the ATP α88

and β-phosphate groups.191 Similarly, a chemical sensor for ADP exhibits a metalion bridging mechanism which specifically binds ADP as compared to ATP and
adenosine, by specifically targeting the phosphate groups in ADP.207 Stojanovic et
al. previously reported a unique adenosine specific aptamer which is engineered
to instill electrostatic hindrance between adenosine di/tri-phosphate and the DNA
phosphate backbone, albeit with a different binding motif which only binds one
molecule per aptamer.86 I propose that substitution of adenine with thymine at
position 23 in the Ade-33 aptamer increases electrostatic hindrance which results
in reduced binding to the phosphate containing adenosine derivatives ATP, ADP
and AMP (fig. 32). It is also possible that substituting thymine for adenine reduces
stacking interactions with neighboring bases, destabilizing the binding pocket for
the larger ATP and ADP molecules.208 Binding of the Ade-33 aptamer with
negatively charged ADP was independent of sodium concentration, thus it is
presumed that the effect of magnesium is primarily as a steric shielding/bridging
molecule and not a result of differences in the DNA backbone stability (Fig. 28).
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Figure 27. Magnesium effect in the binding specificity of Ade-33 and ATP-33
aptamers. (Top) The Ade-33 sequence was highly specific for Adenosine at
magnesium concentrations below 5 mM however at magnesium concentrations
above 5 mM, presumed shielding by magnesium allows binding of ADP with the
concentration of the retention product comparable to adenosine. (Bottom) The
ATP-33 aptamer did not exhibit steric hindrance as magnesium concentrations as
low as 0.25 mM allowed for binding of ADP. The higher negative charge of ATP
was susceptible to steric interactions but could be shielded at even 1 mM
magnesium.
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Figure 28. Effect of sodium on target binding.
The binding of adenosine and ADP to the Ade-33 aptamer was independent of
sodium concentration. This supports the hypothesis that magnesium is primarily
useful as an electrostatic shielding molecule rather than stabilizing the aptamer
structure.
4.3.5

Probing structure-switching functionality with exonuclease I

Large conformational changes between non-binding and binding competent states
in the aptamer structure provide the largest signal gain in electrochemical aptamerbased sensors.48,209 While a more stable aptamer structure might have higher
binding affinity, it will also produce a large background current because the
aptamer will be folded even in the absence of target, bringing the redox probe close
to the surface.48 In contrast, a destabilized aptamer will favor the non-binding state,
reducing the background current and maximizing the signal gain upon target
binding. I utilized the enzyme exonuclease I to test the structure-switching
functionality of aptamer sequences. The activity of exonuclease I on the targetbound aptamer is inhibited because of a significant change in the conformation of
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the aptamer from single-stranded (enzyme active) conformation to rigid doublestranded structure (enzyme inactive). 103,208,210 The observed inhibition products of
the exonuclease III digestion reaction with the extended ATP-33 and Ade-33
aptamers were ordered from IDT DNA. These fragments are 29- and 30-nt in
length, as estimated by utilization of a molecular DNA ladder prepared in-house,
and termed ATP-30, Ade-30, and Ade-29. An additional non-binding mutated
sequence termed Ade-30m was also ordered with identical sequence but with a
single-point mutation that has been shown to inhibit binding.47 All sequence
structures are shown in figure 29. The cross-reactive ATP-30 and the new
adenosine-specific Ade-30 sequences were first incubated with exonuclease I to
determine the structure-switching functionality of these truncated aptamers. In the
absence of target, exonuclease I can quickly digest the aptamer structure of both
the ATP-30 and Ade-30 aptamers, suggesting a single-stranded conformation of
these aptamers in the unbound state. Addition of a binding competent target
results in inhibition of the enzyme reaction because of formation of doublestranded aptamer-target complexes, which are poor exonuclease I substrates. The
ATP-30 sequence exhibited retained products with concentrations of >500 nM for
ATP, ADP and Ade. In contrast, the Ade-30 aptamer only exhibited a retained
product with adenosine of 550 nM, and no inhibition with ATP or ADP (fig. 29c).
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Figure 29. Cross-reactivity testing of a new binding sequence that is specific for
adenosine.
(a) Aptamer products of exonuclease III inhibition-based test. The adenosine
specific aptamer displayed two distinct products with lengths of 29- and 30-nt. (b)
Exonuclease I-based method to identify structure-switching aptamers. The
enzyme exonuclease I has a high degree of selectivity for single stranded
deoxyribonucleic acid (ssDNA), preferentially hydrolyzing ss-DNA over ds-DNA.103
Aptamer-target binding results in structural change of the aptamer conformation
from single-stranded DNA to double-stranded DNA, thus inhibiting digestion by
exonuclease I. (c) Various targets were incubated with the ATP-30 (original) and
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Ade-30 (engineered) aptamer and Exo I was added. All adenosine phosphate
derivatives bound to the cross-reactive ATP-30 aptamer resulting in inhibition
products of the enzymatic reaction. The Ade-30 aptamer was only inhibited in the
presence of adenosine, exhibiting improved specificity for adenosine compared to
ATP and ADP. The inhibition product was plotted as band concentration to
compare the apparent binding affinity to various targets. The band intensity (in nM)
is calculated by comparison to known concentration of control sample and ladder.
(d) The two aptamer fragments of 29- and 30-nt, were tested for structureswitching functionality. Both aptamers are digested by exonuclease I in the
absence of target, suggesting a mostly single-stranded conformation in the resting
state. Upon adenosine binding, the exonuclease I enzyme is inhibited with retained
product concentrations of 600 nM and 350 nM for the 30-nt and 29-nt fragments,
respectively. A mutant non-binding Ade-30m aptamer did not result in inhibition in
the presence or absence of target.
The exonuclease III reaction identifies two aptamer fragments with target-binding
induced inhibition with lengths of 29- and 30-nt. Exonuclease I was utilized to test
the structure-switching characteristics of these two sequences with adenosine.
The Ade-30 aptamer results in adenosine-induced retention of nearly 600 nM of
product while the Ade-29 aptamer only has 350 nM (fig. 29d). However, in the
absence of adenosine the Ade-30 aptamer exhibits reduced hydrolysis, suggesting
intermittent formation of folded structures that are poor substrates for exonuclease
I. The Ade-29 aptamer however, is quickly digested in the absence of target,
suggesting an equilibrium which favors the unfolded, flexible state in the targetfree conformation (fig. 29d).
4.3.6

Structure-switching characterization with circular dichroism

Circular dichroism was utilized to further elucidate the structure-switching
properties of the Ade-29 and Ade-30 aptamers. The Ade-29 sequence exhibited
peaks at 240 nm and 265 nm, corresponding to B-form type DNA structures. The
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longer Ade-30 sequence had increased ipeaks at 240 and 265 nm, corresponding
to formation of folded DNA (Fig. 30). Addition of adenosine gave a distinct
conformational change for the Ade-29 aptamer with increased peak height at 240
and 265 nm corresponding to ds-DNA conformation.

16,211,212

In contrast, addition

of adenosine to Ade-30 resulted in a less drastic shift in the conformation, possibly
because part of the aptamer population is already in a folded conformation (fig.
31).208 An additional control was done with the non-binding sequence Ade-30m to
confirm the structure change was caused by target-aptamer binding and not a
result of an artificial signal. Addition of adenosine to the Ade-30m sequence did
not result in significant changes to the aptamer spectra (Fig. 31).

Figure 30. CD spectra for Ade-29 and Ade-30 without addition of target.
The dsDNA character was higher for Ade-30 which is expected due to its longer
stem which stabilizes the stem-loop binding structure.
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Figure 31. Test of conformational change of Ade-29, Ade-30 and Ade-30m with
Circular Dichroism (CD).
The highest degree of conformational change was observed for Ade-29 which
agrees with previous reports for an ATP binding aptamer.48 A control using a nonbinding sequence (Ade-30m) exhibited only a small change upon addition of
adenosine which confirms that conformational change occurs only through targetinduced aptamer folding.
4.3.7

Characterization of aptamer-target binding with ITC

I utilized isothermal titration calorimetry (ITC) to better understand the binding
properties of the aptamer and the effect of magnesium concentration in relation to
binding. It has been reported that the original ATP-27 aptamer has two binding
sites and weak cooperativity (2 ATP molecules bind per aptamer).197,198 Based on
these assumptions, we utilized a sequential fitting model to analyze ITC data since
the binding sites are different and binding to one site affects the second (i.e.,
Cooperative). We first tested the binding affinity of the Ade-30 aptamer for the
various adenosine derivatives at a low magnesium concentration (1 mM) and
identified two adenosine molecules bind per aptamer with negative cooperativity,
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like previously reported studies.110 Under these conditions, the binding affinity was
strongest for adenosine and weakest for ATP with equilibrium dissociation
constants of 8.9, 64 and 115 uM for adenosine, ADP, and ATP, respectively (fig.
32b) which correlated well with the observed enzymatic results. However, at high
magnesium concentration (10 mM) these effects are attenuated with similar
binding affinity for Ade, ADP and ATP presumably due to steric shielding by
magnesium with equilibrium dissociation constants of 9.5, 18.2, and 27.1 uM for
adenosine, ADP and ATP, respectively (Fig. 33). For the cross-reactive ATP-30
aptamer, strong binding of ADP and ATP targets occurred even at magnesium
concentrations as low as 0.5 mM with dissociation constants of 2.9 and 5.0 uM for
ADP and ATP, respectively (fig. 32b). These results suggest a possible interaction
between the adenine at position 23 and the phosphate groups of ADP and ATP for
stabilization instead of requirement for magnesium. We presume that the negative
charge and size of AMP(-2), ADP (3-) and ATP (4-) play a role in the unfavorable
binding for these molecules as compared to adenosine (neutral) at the buffer pH
of 8.5.213 Experiments with mutant non-binding aptamer sequences (Ade-30m and
ATP-30m) resulted in loss of binding with all the targets (data not shown). ITC and
electrophoresis results outline the importance of magnesium to stabilize binding of
the ADP and ATP molecules to the engineered adenosine-specific aptamer
presumably through a bridging/shielding interaction and the ability of the Ade-30
aptamer to bind adenosine specifically at low magnesium concentrations (fig. 32a).
Binding of all targets resulted in a small enthalpy change upon binding of the first
target molecule and a larger enthalpy change upon binding of the second target
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molecule. This could be a result of the first Adenosine stabilizing the stem-loop
structure through hydrogen bonding with a nucleotide in the aptamer sequence
and the second adenosine further stabilizing the rest of the structure resulting in a
zipping mechanism of the binding pocket. This correlates well with the entropy
change which is large and negative for the second binding event, which is likely
from a conformational change in the aptamer structure (fig. 32b). It should be noted
that the negative entropy change was smaller for the ATP-30 sequence,
suggesting a more stable stem structure prior to binding the second target.

Figure 32. Proposed mechanism of Ade-30 specificity for Adenosine due to steric
hinderance with ATP and ADP at low magnesium concentration.
(table 1) ITC binding affinity measurements for adenosine, ADP, and ATP. The
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buffer conditions were chosen to match the enzyme-based conditions. (10 mM
BTP, 0.5-1 mM MgCl2 at pH 8.5). The DNA concentration in the cell was 20 µM
and the concentration of small molecule in the syringe was 650 µM. A sequential
binding model was used to fit and analyze the binding curves.

Figure 33. ITC binding experiments at 10 mM magnesium for the Ade-30
sequence.
Under conditions of high magnesium there is significant binding for all targets
although it appears ATP has weaker binding. This is presumably due to the steric
shielding effect of magnesium.
The Ade-29 aptamer displayed strong binding affinity for adenosine with a
dissociation constant of 20, 131 and 173 µM for adenosine, ADP and ATP,
respectively (fig. 34). The measured affinity was 2-fold higher for Ade-30 as
compared to Ade-29. This is consistent with the fact that Ade-29 has an energy
penalty to reach a binding competent state. We chose the Ade-29 aptamer to
design a redox-modified aptamer for electrochemical sensing since it could bind to
adenosine with relatively high affinity and maximize the signal change upon target
binding with a large change in structure conformation.
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Figure 34. Binding affinity of Ade-29 to adenosine, ADP and ATP under optimal
binding conditions (10 mM BTP, 1 mM magnesium at pH 8.5).
The binding affinity was reduced by 2-fold for all targets when compared to the
Ade-30 aptamer.
4.3.8

Design of methylene-blue modified aptamer sequence (Ade-29-MB)

In blood or serum, spectroscopic methods are seldom utilized because of
significant interference from the matrix complicating sensitive measurements in
undiluted samples.176,193 Therefore, I adapted the Ade-29 aptamer for
electrochemical sensing which is both sensitive and highly selective, readily
applicable for detection in undiluted complex samples.10 Electrochemical aptamerbased signaling is a result of specific target-induced changes in the conformation
of an aptamer immobilized to an electrode surface and covalently labeled with an
electroactive molecule, producing a current change that corresponds to target
concentration.192,214,215 The redox molecule methylene blue was covalentlyattached to the 3’ end of the Ade-29 aptamer while the 5’ end was chemically
modified with an alkane thiol. To ensure close contact between the methylene blue
and electrode surface, the Ade-29-MB aptamer was modified with three additional
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thymine residues at the 3’ end to match the non-binding residues at the 5’ end that
are conserved from the previous enzymatic experiments (fig. 35). In the absence
of target, the Ade-29-MB structure is flexible, placing the redox tag away from the
electrode and inhibiting electron transport. Target-induced changes in the structure
result in folding of the aptamer, bringing the redox tag in proximity to the electrode
surface and increasing the measured current. The advantages of this platform is
that it enables sensitive sensors with large signal gain, provides a large degree of
selectivity because only the aptamer redox element is active in the potential
window employed and is indifferent to non-specific binders or contaminants that
might absorb on the electrode surface.181,215

Figure 35. Design of methylene blue modified adenosine aptamer sequence: Ade29-MB.
The aptamer is functionalized with a thiol group on the 5’ end to immobilize onto a
gold electrode surface through strong thiol-gold bonds. The 3’ end of the aptamer
is functionalized with the electroactive molecule methylene blue (MB). The 5’
extension of the aptamer is kept intact from the enzyme-selected structure and
three thymine non-binding nucleotides are added to the 3’ end to match the
number of nucleotides on the 5’ end, allowing close contact between the MB and
the electrode surface upon target-induced folding of the aptamer structure.
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4.3.9

Electrode surface modification and effects on signaling

Initially, we prepared the Ade-29-MB-based sensor using a previously reported
method of surface modification with 6-mercapto-1-hexanol (MCH).94 MCH can
remove non-specifically bound aptamer molecules from the gold surface and lead
to a more organized monolayer and large population of “active-sensing”
aptamers.95 The results were promising, with addition of adenosine leading to a
large positive change in the current while addition of ADP and ATP did not change
the current (Fig. 36). The sensor was slightly cross-reactive for ATP and ADP when
performing detection in a buffer with 1 mM magnesium, which could be a result of
the higher local magnesium concentration at the electrode surface and nonspecific
folding of the aptamer even in the absence of the target.195 Therefore, we
performed the rest of the testing in buffer without any magnesium which resulted
in minimal cross-reactivity (Fig. 36). Sodium was added to aid in conductivity of the
solution but it did not cause any effect on target binding (fig. 37).

Figure 36. Platform for electrochemical sensing of adenosine using the adenosine
specific Ade-29-MB aptamer.
(a) In the absence of adenosine, the redox probe is far from the electrode surface,
thus only a small current is produced through the flexibility of the probe which can
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strike the surface at a slow rate. A target-induced change in the aptamer
conformation results in folding of the aptamer, bringing the redox tag into proximity
of the electrode surface and increasing the rate of electron transport and thus the
measured current. There is an equilibrium between the non-binding state (ss-DNA)
and the binding competent state which directly affects the binding affinity and the
background current. (right) Output current from addition of different targets ([target]
= 250 µM) as detected by Ade-29-MB. Only specific binding of adenosine results
in an increase in the measured current.

Figure 37. Magnesium and sodium effect on electrochemical detection.
Aptamer specificity is reduced in electrochemical measurements in the presence
of 1 mM magnesium. This is likely a result of increased local concentrations of
magnesium at the electrode surface, which is negatively charged. The specificity
can be regained by lowering the magnesium concentration in the buffer. Sodium
did not affect the electrochemical signaling.
Aiming to increase the signal gain of the sensor, we tested a combination of MCH
and dithiothreitol (DTT) as backfillers, with DTT being able to fill most pinholes in
the monolayer structure reducing noise and displacing non-specifically bound
nucleotides as well as increasing inter-aptamer distances which could aid in target
binding.98,216 Interestingly, we observed higher signal gain with a combination of
MCH/DTT as compared to MCH or DTT alone (Fig. 38a). The higher signal gain
resulted in better performance at low concentrations of adenosine, enhancing the
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sensor sensitivity (fig. 38b). This is a result from lower background current as well
as higher signal gain upon target binding which could be explained by better
monolayer stability, reduced non-specific interactions between the aptamer bases
and the electrode surface and better aptamer spacing on the gold surface.216
Dithiothreitol (DTT) alone significantly increased the electron transfer rate similarly
as to what was previously observed by using short alkyl-chain backfillers, but
resulted in lower signal gains because of increased background current.97 The
aptamer surface coverage on the gold electrode was similar for MCH, MCH/DTT
and DTT, therefore it is unlikely that the signal enhancement was a result of more
probes being present on the surface (Fig. 38c). Signal response and equilibration
times were also improved with the mixed monolayer of MCH/DTT as compared to
MCH (data not shown). The amplitude was also optimized, with 25 mV resulting in
the best signal gain (fig. 38d). It is possible that the mixed monolayer could be
generally applied to other aptamer sensors but further investigation is required to
understand whether this effect is specific for the Ade-29-MB aptamer.
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Figure 38. MCH and DTT effect on electrochemical sensor and optimization.
Various backfiller molecules were utilized to stabilize the gold-aptamer monolayer.
(a) A combination of MCH/DTT resulted in the highest signal gain sensors at all
frequencies tested. This is likely a result of better inter-aptamer spacing and lower
non-specific adsorption of molecules to the electrode surface. (b) The MCH/DTT
combination has better analytical performance, specially at lower adenosine
concentrations, with higher apparent binding affinity. (c) The surface coverage was
unchanged regardless of the backfilling molecule. This suggest that any
improvement in the signaling is not a result of number of DNA aptamers
immobilized on the surface of the electrode. (d) The amplitude of MCH/DTT
modified electrodes was optimal at 25 mV at all frequencies.
4.3.10 Detection of adenosine in undiluted and unprocessed serum
Calibration curves were collected by titrating targets into a 4-mL electrochemical
cell (Fig. 39). A hill binding model was utilized for fitting the titration curves which
resulted in an apparent binding affinity slightly lower than ITC likely because
detection was performed in buffer without magnesium and the surface
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immobilization often affects affinity. We observed a weak cooperativity from the
fitting which corresponds well with other reported methods and our own ITC data.
Signal saturation was reached around 1 mM with a signal maximum of 120% and
with a linear range from 1-50 uM in buffer (Fig. 39a and b). The frequency was reoptimized for detection in whole serum to account for the change in viscosity of the
solution which has previously been reported to slow the rate of electron trasnfer.192
However, the results indicated that the optimal frequency was also 100 Hz. in
whole serum (Fig. 39a). We could perform detection immediately after target
addition and observed complete signal saturation after 30 seconds (Fig. 39c).
Signal saturation was also around 1 mM in undiluted serum with a linear range
from 1-100 uM (fig. 39c). Detection in serum resulted in reduced signal gain
because of the endogenous concentration of magnesium and other ions. The
magnesium concentration in serum is reported to be between 1 - 4 mM. This
produces a higher background current presumably because of stabilization of the
binding competent state in the absence of target accounting for about 20% signal
loss (Fig. 40c). The rest of the difference is attributed to the viscosity of the serum
and possible degradation of the reference electrode. Measurements in undiluted
serum also present higher cross-reactivity because of the endogenous magnesium
concentration (Fig. 40c). Simply adding EDTA (2.5 mM) to the detection solution
to quench the endogenous magnesium is sufficient to regain the desired specificity
(Fig. 40c). Under such conditions, adenosine detection is specific compared to
ATP, ADP, AMP and GTP (fig. 41) even under significant differences in the
concentration of the targets.
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Figure 39. Electrochemical detection of adenosine in buffer and serum.
(a) Calibration curve of adenosine in buffer with linear range (inset) between 1 –
50 µM and a maximum signal gain of 120% (b) Raw current response from SWV
experiment with increasing concentrations of adenosine. (c) Calibration curve for
adenosine in undiluted serum spiked with increasing concentrations of adenosine
reported as signal gain percentage with linear range between 1 – 50 µM(inset). (d)
Comparison of normalized signal gain and specificity of adenosine over ATP and
ADP in buffer and undiluted serum with 2.5 mM EDTA and 500 µM of each target.

Figure 40. Serum optimization and cross-reactivity in undiluted serum.
(a) Frequency optimization in whole serum exhibited an optimal of 100 Hz. which
was utilized for all other experiments. (b) Signal gain over time in undiluted serum.
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Adenosine detection can be performed immediately after target addition and with
signal saturation within 30 seconds. (c) Cross-reactivity in serum presumably
because of endogenous magnesium and other divalent ions. EDTA can be added
to quench the free divalent ions in undiluted serum to regain the desired specificity.
[Target] = 500 µM.

Figure 41. Adenosine specific detection and cross-reactivity with ATP, ADP, AMP
and GTP.
The Ade-29-MB aptamer is highly specific for adenosine when compared to ATP,
ADP, AMP and GTP. AMP has even lower interaction with the aptamer, likely due
to strong repulsion between the alpha phosphate and the thymine at position 23.
[Target] = 250 uM
4.4 Conclusion
Initially, we hypothesized that nucleotide substitutions near the binding site would
modulate the aptamer specificity. Indeed, our new adenosine aptamer varies at a
single nucleotide and displays over 10-fold higher affinity for adenosine compared
to ATP. The sensor was utilized to measure adenosine in undiluted serum with
nearly no response for ATP or ADP, demonstrating its potential use in medical
settings with similar performance as compared to buffer. The Ade-29 aptamer
exhibits increased specificity for adenosine while retaining the same stem-loop
structure of the original aptamer. The ability to use the same aptamer stem-loop
structure is valuable as many methods have been developed for this structure and
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sufficient characterization has been published, opening the door for further
increasing the sensitivity of the sensor with adaptation to different signaling
mechanisms. For example, graphene-based methods can be readily used with our
structure-switching aptamer. The potential applications for this sensor will be in
directly measuring adenosine in blood/serum samples to diagnose potential
diseases, as a research lab tool in studies of the role of adenosine in various
diseases, and potential identification of new therapies where adenosine
concentration is important. We also envision the use of this sensor to indirectly
measure the activity of adenosine regulating enzymes such as adenosine
deaminase (ADA), adenosine kinase (ADK) and S-adenosylhomocysteine
hydrolase (SAHH) and profiling of potential inhibitors of these enzymes. All of this
is a direct result of the ability of the aptamer to measure adenosine in the presence
of ATP, ADP, and AMP, which are the major sources of adenosine. Limitations of
the newly identified Ade-29 aptamer include the increased cross-reactivity in the
presence of high concentrations of magnesium which likely prohibits its use in
continuous detection for neuromodulator release measurements in its current state
and its limited sensitivity. We believe these obstacles can be overcome with further
engineering of the aptamer sequence, improvements to the electrochemical
detection method and adaption to different read-out methodologies.
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CHAPTER 5
Nuclease-guided truncation of aptamers for optimal structure-switching
functionality and application in electrochemical sensors
Aptamers which do not undergo conformational changes upon target-binding
cannot be easily incorporated into signal transduction mechanisms. Conventional
methods to instill structure-switching functionality -to otherwise conformationally
static aptamers- often involve meticulous and labor-intensive testing of various
‘pilot’ sequences. To enhance, facilitate, expedite and lower the cost of finding
optimal structure-switching aptamers, we employ a T5-exonuclease guided
method that truncates conformationally static aptamers, yielding aptamer
sequences with large difference in the target-bound and un-bound states, with
target-induced change in the conformation. The method was demonstrated to
generate aptamer sequences with target-induced structure-switching functionality
for the schedule I drug methylenedioxypyrovalerone (MDPV) and medical
biomarkers deoxycorticosterone 21-glucoside (DOG) and adenosine triphosphate
(ATP). Incredibly, identification of an optimal truncated aptamer can be achieved
in a single experiment, from a single aptamer parent sequence. Additionally, DNA
without expensive purification can be utilized, providing a low-cost alternative to
generate optimal structure-switching aptamers. The method provides a key tool in
development of E-AB sensors by lowering the cost, development time and
complexity of aptamer engineering for electrochemical transduction.
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5.1 Introduction
Electrochemical aptamer-based (E-AB) sensors are becoming increasingly
popular for detection of various targets in complex sample matrices (e.g., human
serum and adulterated drugs).10,90 Functionality in complex samples is provided by
the incredible specificity of aptamers, which can recognize even small changes in
the structure of a molecule, and the high selectivity of electrochemistry because of
the paucity of electroactive species in most samples.194 The success of these
sensors largely lies in the ability to couple the binding reaction -between analyte
and aptamer- into a measurable electronic signal (i.e., current). Electrochemical
signaling occurs via a target-induced conformational changes in the aptamer
structure, which modulates the rate of electron transfer between an electroactive
molecule (covalently modified onto the aptamer) and the immobilizing electrode
surface (Scheme 1).215 Transfer of electrons (i.e., signal-output) is determined by
the distance of the redox-tag from the electrode surface and flexibility of the
aptamer structure -both phenomena are directly affected by the aptamer
secondary structure (i.e., conformation).92
Aptamer selection strategies often isolate aptamers with relatively fixed (i.e., semipermanent) conformations, which do not undergo target-induced structureswitching. Therefore, development of E-AB sensors requires meticulous and
expensive aptamer engineering to impart structure-switching functionality to
otherwise highly stable (i.e., folded) aptamers.48,110 The most important factor for
optimizing the signal gain in E-AB sensors is finding the correct aptamer sequence
which can ‘switch’ between distinct conformations before and after target binding.
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Scheme 1. Electrochemical aptamer-based (E-AB) sensor design.
Aptamers can be chemically functionalized with an alkane-thiol group for
immobilization onto electrode surfaces by strong thiol-gold bonds, preventing
desorption of aptamers during fabrication and measurements. The short alkanethiol functional group also provides stabilization during formation of the aptamer
monolayer by hydrophobic interactions with a diluent alkane-thiol molecule
(omitted for clarity, see chapter 4 for detailed structure). The opposite end of the
aptamer is chemically modified with an electroactive molecule such as methylene
blue. The aptamer functions as a target-sensitive ‘switch’, separating the
electroactive molecule from the electrode surface and thus modulating the
measured current as a function of analyte concentration.
A method that can add structure-switching functionality to the currently available
and extensive aptamer library is highly desirable. While aptamer isolation methods
for direct selection of structure-switching aptamers have been previously reported
with limited examples and applications, adapting the already available and
extensive library would be immediately impactful.217 The main advantages of
structure-switching aptamers are their remarkable specificity (since weak-binding
and non-binding molecules don’t typically induce structure-switching) and their
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compatibility with various transduction methods such as fluorescence, colorchange and electrochemistry. Generally, conventionally isolated DNA aptamers
form stable, folded structures with distinct geometries such as stem-loops and
three-way junctions; in both cases, intramolecular helices stabilize formation of a
binding pocket, such as a three-way junction (three stems stabilize a central
binding pocket). Prediction of the lowest energy conformation is based on
calculations of the energy stabilization of individual matched base-pairs and
energy penalties of loops, non-binding nucleotides or mismatched base pairs.218
Increasing the number of matched base-pairs shifts the conformational equilibrium
towards a folded conformation while removal of stabilizing base-pairs or addition
of mismatched base-pairs would destabilize the structure until an unfolded
structure is favored (Scheme 2).

Scheme 2. Stem-length effect on aptamer conformation.
Aptamer structures with long stems are highly stable and almost completely folded
into organized and rigid double-stranded structures with little conformation
difference upon target-binding. As the number of stabilizing base-pairs in the stem
is reduced, the aptamer is destabilized and unfolds into a disorganized and flexible
structure of single-stranded DNA. A minimum number of base-pairs is required for
target-binding, with conventional methods requiring complex and costly aptamer
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re-engineering to discover the correct structure-switching sequence and structure.
Several strategies have been demonstrated to instill structure-switching
functionality to aptamers including: (a) destabilization by trial-and-error truncation
or mutation of the native aptamer structure such as removing base pairs or adding
mismatched nucleotides, (b) separation of the folded binding pocket by addition of
a polymer linker or long sequences of non-binding nucleotides and (c) addition of
a competing oligonucleotide strand that will hybridize with the aptamer, block the
binding site, and lock the aptamer in a distinct open conformation. The competing
oligo strand can be displaced by target-specific binding (Scheme 3). These
processes require careful and meticulous design, re-engineering and expensive
testing of various aptamer sequences to find the sensitive equilibrium between the
non-binding

state

and

the

bound-state.48,101 Additionally,

such

aptamer

engineering can often lead to degradation of the analytical characteristics of the
aptamer. For example, Li et al. developed and utilized a competitive DNA strand
strategy (scheme 3c) to develop a structure-switching aptamer for ATP detection.
The affinity of the partially blocked aptamer is heavily affected, with a reported
reduction in the equilibrium dissociation constant by up to 60-fold, an effect of
competition with the oligo strand.83 Indeed, the length of the competing strand must
be carefully designed otherwise the target will not be able to bind to the aptamer.
This method is also not conveniently adaptable to E-AB sensors since it requires
addition of exogenous reagents and long incubation times to hybridize the
immobilized probe to the competing oligonucleotide strand. Elsewhere,
destabilization and addition of linking groups to separate binding sites have also
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been explored. White et al. engineered various derivatives of the original ATP
aptamer to compare the effects of destabilization and pseudo-sandwich (bridged)
designs (scheme 3, a and b).48 They concluded that destabilization provided the
highest signal gain sensors, with ease of adaptability to E-AB sensing since the
aptamer does not require any exogenous reagents for detection. White et al. also
reported destabilization by truncation of the cocaine aptamer for efficient targetinduced sensing and similar results for the thrombin aptamer.87

Scheme 3. Methods to add structure-switching function to aptamers.
Most reported aptamers display stable, mostly folded structures with long regions
of rigid intramolecular helices (i.e., dsDNA). These aptamers adopt a semipermanent and optimal conformation to minimize energy barriers to bind the
analyte. Several strategies have been developed to change the resting
conformation including: (a) removing stabilizing base pairs from stem regions,
causing unfolding of the aptamer structure that can only be repaired by target-
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aptamer binding. (b) Addition of long linker bridges that divide the binding motif
into distinct sites that can only be reunited upon target addition. (c) Addition of a
competing strand that blocks the binding site but can be displaced by targetinduced aptamer folding.48
Destabilization by truncation of various aptamers has resulted in aptamers that
exhibit structure-switching functionality and have been successfully incorporated
to E-AB sensors. Unfortunately, design of such structures requires prior knowledge
of the secondary structure of the aptamer and meticulous and expensive testing of
multiple ‘pilot’ sequences.48,101 We describe a nuclease-based method that
truncates the aptamer structure but is inhibited close to the binding site by
formation of target-aptamer complexes, yielding aptamer sequences with
structure-switching functionality without requiring complex, lengthy and expensive
aptamer engineering.
Several purified enzymes exhibit exquisite specificity for hydrolysis of distinct DNA
conformations (e.g., single-stranded vs. double-stranded DNA). For example, Lou
et al. employed exonuclease I, which hydrolyzes single-stranded DNA but not
double-stranded DNA, to create sensors for various aptamer targets including the
small molecule cocaine. The employed aptamers exhibited disorganized and
flexible structures prior to target binding that were susceptible to hydrolysis by the
exonuclease I; Binding of target resulted in folding of the aptamer to a rigid doublestranded structure that was not susceptible to hydrolysis by exonuclease I. The
undigested aptamer product could be quantified by addition of a DNA-binding
fluorescent dye, with increasing fluorescence being proportional to target
concentration in the sample.157 Unfortunately, the method requires prior
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knowledge of the folding dynamics of the aptamers and predicted structure
changes upon target binding. Wang et al. recently described an exonuclease IIIbased system to instill structure-switching functionality to small molecule
aptamers. Exonuclease III can digest double-stranded DNA specifically from blunt
or recessed 3’ ends in the 3’ to 5’ direction; Surprisingly, aptamer-target complexes
inhibit digestion by exonuclease III 4-nt (nt: nucleotides) away from the presumed
binding site.110 Enzyme truncation of several nucleotides yielded aptamers
sequences with shorter stabilizing stems that were proven to undergo structureswitching functionality. Similarly, we developed a method utilizing T5 exonuclease
as a catalyzing molecule to probe DNA aptamer conformation in the 5’ to 3’
direction to identify optimal structure-switching aptamer sequences. T5exonuclease has been previously shown to catalyze the hydrolysis of linear singlestranded DNA, double-stranded DNA, 5’ overhangs and 3’ overhangs in the 5’ to
3’ direction.111,112,114,219–221 Thus, T5 exonuclease is an excellent complement to
exonuclease III, which acts in the 3’ to 5’ direction with similar enzymatic activity. I
hypothesized that T5 exonuclease would be inhibited close to the presumed
binding site by formation of aptamer-target complexes as its observed in the
exonuclease III system. In the absence of target, the enzyme will freely track along
the DNA sequence from the 5’- end and catalyze the hydrolysis of the aptamer
molecule with activity for both the single- and double-stranded DNA aptamer
conformations. In contrast, formation of an aptamer-target complex will inhibit the
enzyme progress close to the binding site, providing truncation of the parent
aptamer and yielding a minimal-length aptamer sequence which is preferentially
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unfolded in the absence of target, but can readily form a stable, enzyme-inhibiting
folded structure upon target-binding. Herein, T5 is utilized to smartly truncate
aptamers to yield structure-switching aptamers for small molecules including the
synthetic cathinone MDPV and medical biomarkers DOG and ATP.
5.2

Methods

T5 Exonuclease was purchased from New England Biolabs (10 U/µL) and stored
in 5 µL aliquots at -30°C. Methylenedioxy pyrovalerone (MDPV) was purchased
from Cayman Chemicals. Stock solutions were prepared in 100% methanol at
concentrations of 32 mM and stored at -30°C. ATP was prepared in a buffered
solution at a concentration of 37 mM, as measured using absorbance and an
extinction coefficient of 15.4 mM-1. DOG and DIS were prepared in 100% DMSO
and stored at -30°C. Oligonucleotide sequences were purchased form IDT-DNA
without purification with only standard desalting. DNA stock solutions were
prepared by dissolving in nuclease-free water with average concentrations of 100
µM. DNA concentration measurements were performed in a Nanodrop instrument
with the specific extinction coefficient as provided by the company. Stocks were
stored at -30°C in 5 µL aliquots. The following sequences were utilized:
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Table 4. DNA sequences, substitution and mutations.

Note: Red outline indicates the conserved aptamer binding sequence for DOG.
5.2.1

T5 enzyme reaction

DNA stocks were first diluted to 1 µM and placed on a hot plate at 95°C for 10
minutes to completely denature the aptamer structure. The DNA solution was then
placed in ice to obtain the lowest energy, folded sequence. The buffer employed
for the enzymatic reaction was NEB-4 as suggested by the company for optimal
catalysis (1x NEB-4: 20 mM tris-acetate, 50 mM potassium-acetate, 10 mM
magnesium acetate, 1 mM dithiothreitol (DTT) at pH 7.9). The aptamer mixture
was then incubated with the appropriate target for 30 minutes at 23°C. MDPV stock
solution was prepared by vacuum centrifuging to evaporate the methanol solution
and isolate the solid MDPV. Water was added to the MDPV solid to appropriately
match the desired concentration. T5 enzyme was diluted on ice to a final
concentration of 1 U/µL and added to a 90% buffer mixture with DNA:enzyme ratio
of 1 µM:0.1U/µL. The mixture was manually mixed and centrifuged prior to
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incubation at 23°C. The reaction was stopped at various times by dilution with a
stop mix gel loading buffer consisting of 3.5 M urea and 50% formamide. (1 part
DNA: 4 parts loading buffer)
5.2.2

Gel Electrophoresis

Denaturing gel electrophoresis (8M urea) was performed to separate and analyze
the enzymatic reaction products. Polyacrylamide gels were prepared by mixing 5
mL DI, 10 mL 5X TBE and 20 mL (40% acrylamide) with 21 g of Urea. The solution
was mixed on a hot plate at 30°C until the urea dissolved. Freshly prepared 10%
APS and TEMED were then added and polymerization occurred at room
temperature for 2 hours. The gels were pre-run at 450V and the final sequence
analysis was a two-step method, 100V for 30 minutes and 400V for 3 hours.
Samples were loaded as prepared during the enzymatic reaction, 4 µL per well.
DNA markers were prepared in-house by mixing sequences with increasing
lengths and matching the concentrations to obtain a uniform band intensity.
Ladders were appropriately loaded to calculate the length of resulting products.
Band intensity was compared to a control band without any enzyme to estimate
the concentration of products.
5.3 Results and discussion
5.3.1

MDPV aptamer truncation

T5 exonuclease is utilized to probe the aptamer structure in the 5’ to 3’ direction
because of its ability to catalyze the hydrolysis of linear single-stranded and
double-stranded DNA conformations.112 I hypothesized that T5 exonuclease would
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be inhibited close to the presumed binding site by formation of aptamer-target
complexes. We utilized a novel methylenedioxy pyrovalerone (MDPV)-binding
aptamer that was recently selected in our lab as a test bed. The enzymatic reaction
was monitored by denaturing gel electrophoresis to identify the enzyme products
and estimate their length by comparison to a DNA-marker. In the absence of
MDPV, T5 can hydrolyze the aptamer structure yielding short oligonucleotide
enzymatic product fragments of 21- and 22-nt (where -nt stands for nucleotides).
Aptamer binding to the MDPV target severely inhibited T5 close to the presumed
binding site, with a main enzyme reaction product of 41-nt, which is 5-nt less than
the starting parent aptamer of 46-nt (Fig. 42a). Prior to T5-guided truncation, the
aptamer stabilizing stem consists of 8-base pairs, most of which are presumably
not involved in binding to the target but still stabilize the folded conformation and
possibly prevent structure-switching upon target-binding (Fig. 42b). After T5guided truncation, the aptamer stem is reduced to 3-base pairs, which appears to
be the minimum stem-length required for binding to the MDPV target. It is well
established that reducing the stem length leads to increased possibility of
structure-switching functionality, thus it is likely that the T5 truncation product can
undergo structure-switching upon target-binding (fig. 42b, bottom).48,62,102 For
quick comparison of the enzymatic reaction products, the aptamer structure is
color-coded. In the absence of target, the enzyme reaction product is represented
by a red outline. In the presence of target, the enzyme reaction product is
represented as a combination of the red and a blue outline.
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Figure 42. T5-guided truncation of an MDPV-binding aptamer yielding a structureswitching sequence.
(a) T5 exonuclease was utilized to digest the MDPV-aptamer. In the absence of
target, T5 catalyzes the hydrolysis of the aptamer structure, yielding short
fragments of 22- and 21-nt. Formation of an MDPV-aptamer complex inhibits T5
activity 3-nt away from the presumed binding site, producing a distinct product of
41-nt. A control band is shown without addition of enzyme and a DNA marker is
utilized to approximate the length of the enzymatic products. (b) The originally
selected aptamer displays a long stabilizing stem which prevents target-induced
structure-switching (top). The T5-truncated aptamer has a much shorter stabilizing
stem of 3 base-pairs which possibly exhibits target-induced structure-switching
(bottom). The colored lines indicate the enzyme reaction products in the absence
(red; 19- and 20-nt) and presence (blue + red; 41-nt) of MDPV. [T5] = 0.1 U/µL,
[DNA] = 1 µM, [MDPV] = 320 µM at 23°C for 120 minutes.
The T5 reaction was stopped at different times by mixing with formamide and
EDTA to examine the reaction products over time. A control sample of constant
concentration was utilized to estimate the concentration of the enzymatic products.
In the absence of a binding target, several enzymatic products are observed over
a time window of five hours. In the absence of target, T5 reaction for 15 minutes
yields a singular 41-nt product with an estimated concentration of 800 nM (80% of
122

the starting material). Interestingly, the 41-nt product is still present even after two
hours of reaction, suggesting the enzyme unbinds with the DNA at this point
possibly because of a change in the conformation of the structure and must rebind to digest the new aptamer conformation. After 120 min, the 41-nt product is
only faintly present with a concentration of 100 nM and it is eventually completely
digested after 5 hours (fig. 43). In contrast, two reaction products are observed
after 15 minutes of incubation with T5 in the presence of MDPV with lengths of 42nt and 41-nt and concentrations of 450 nM each (fig. 43, plotted as a combined
concentration). After 120 minutes, most of the 42-nt product is enzymatically
converted to the 41-nt product and the estimated concentration of the 41-nt product
at this point was 600 nM (fig. 43). Even after 5 hours of T5 digestion, the MDPVaptamer mixture exhibits a 41-nt product with an estimated concentration of 550
nM (fig. 43). Thus, we proved that formation of MVPD-aptamer complex inhibits
T5 activity and the inhibition product of 41-nt possibly has different conformations
in the absence and presence of MDPV. This method can possibly identify a
structure-switching aptamer in a single experiment, without requirements for
complex aptamer engineering or labor-intensive testing of multiple sequences.
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Figure 43. Time course of T5 reaction and characterization of enzyme reaction
products visualized utilizing gel electrophoresis.
T5-exonuclease can quickly digest nucleotides that are not involved in binding to
the target and within two hours most of the parent aptamer is hydrolyzed in the
absence of target. However, in the presence of MDPV, formation of the aptamertarget complex inhibits T5 digestion and results in a truncated product of 41-nt.
This suggests that formation of a folded aptamer-target complex inhibits the
enzyme progress. The intensity of the bands is converted to concentration by
comparing to the control band which has a known concentration. [T5] = 0.1 U/µL,
[DNA] = 1 µM, [MDPV] = 320 µM at 23°C.
To confirm that T5 inhibition is a result of formation of MDPV-aptamer complexes
and not a result of direct inhibition by MDPV, we designed truncated sequences of
the MDPV aptamer which do not form the presumed hydrophobic binding site. The
MDPV aptamer structure was manually truncated by deletion of 10- and 13-nt from
the 3’ end yielding aptamer variants of 36-nt and 33-nt. The predicted folding was
calculated with Mfold, a webserver to predict nucleic acid folding, to predict
whether the three-way junction could be formed in the 33- and 36-nt aptamer
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variants.222 These shorter fragments are not predicted to form a three-way junction
because of the absence of complementary base-pairs, inhibiting target binding
(see Mfold predicted structures in figure 44). T5 truncation of the non-binding
sequences resulted in reaction products that were identical whether in the
presence or absence of MDPV. For example, the 36-nt aptamer exhibited a main
product of 28-nt and a concentration of 175 nM, about 17% of the starting material
in the presence or absence of MDPV (fig. 44). The 33-nt aptamer after T5
truncation yielding a major product of 25-nt regardless of the absence or presence
of MDPV. T5 is only inhibited when the 46-nt binding aptamer is utilized, with a
41-nt inhibition product of >500 nM (fig. 44). Thus, the inhibition of T5 is directly
caused by binding of MDPV to the aptamer. To easily visualize and compare the
products of the enzymatic reaction to the starting structure, a color-guide outline is
utilized. For example, the starting aptamer of 46-nt is a combination of the gray,
red and blue outlines. T5-exonuclease removes 5-nt from the starting structure
yielding a main product of 41-nt in the presence of MDPV, represented by the blue
and red outlines combined. In the absence of target, the main products are shown
in a red outline, with lengths of 22- and 21-nt (Fig. 44, bottom). From this scheme,
it can be observed that only the 46-nt aptamer bound to MDPV inhibits T5 activity
and yields a different product in the presence of MDPV.

125

Figure 44. T5 inhibition is caused by formation of a MDPV-aptamer complex and
not by MDPV itself.
(a) Gel electrophoresis enzyme products of different aptamer sequences in the
presence and absence of target. The truncated non-binding sequences (33-nt and
36-nt) do not exhibit any MDPV-induced inhibition. However, the 46-nt binding
aptamer exhibits significant MDPV-induced inhibition of T5 digestion with a
singular product of 41-nt and concentration of >500 nM (represented by the blue
and red outline combined). In the absence of target, short products of 22- and 21nt are observed (represented by the red outline). [T5] = 0.1 U/µL, [DNA] = 1 µM,
[MDPV] = 320 µM at 23°C for 120 minutes.
5.3.2

Comparison with T7-exonuclease

Enzymatic inhibition by formation of aptamer-target complexes has been
demonstrated with exonuclease III (3’-5’ direction) previously and with T5exonuclease (5’-3’ direction) in this work. To study whether this is phenomenon is
generalizable, I employed T7-exonuclease to determine if aptamer-target
complexes could also inhibit T7 activity. T7-exonucelase has been widely reported
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to have incredible specificity for double-stranded DNA, with activity from blunt or
recessed 5’ ends.223–225 Indeed, a singular mismatched base-pair can result in
inhibition of T7 enzymatic activity.226 I hypothesized that T7 would be able to
hydrolyze aptamer structures with stable stems but be inhibited close to the binding
site as observed with T5 and exonuclease III. We tested the same 46-nt MDPVbinding aptamer to compare T5 and T7 for aptamer truncation. T5 can truncate the
aptamer to yield a product of 41-nt in the presence of MDPV but T7 is not able to
digest the aptamer structure in the absence or presence of target (fig. 45). Even
after 4 hours of T7 reaction, the same parent aptamer is observed suggesting the
enzyme is not able to catalyze hydrolysis of this aptamer structure even though it
exhibits a favorable double-stranded substrate. It is notable that T7 exonuclease
does not have activity for single-stranded DNA. In contrast, both T5-exonucelase
and exonuclease III have both single- and double-stranded activity. At least in this
case and under the current experimental conditions, it appears that only T5
exonuclease is capable of aptamer truncation.
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Figure 45. Comparison of aptamer truncation with T5- and T7-exonuclease.
Two enzyme-based methods were tested with the MDPV binding aptamer. As
expected, T5 could differentiate between aptamer-bound and aptamer-free
structures. However, T7 did not digest either structure even though it has been
previously reported to be highly specific for double-stranded DNA. [T5] = 0.1 U/µL,
[T7] = 0.2 U/µL, [DNA] = 1 µM, [MDPV] = 320 µM at 23°C.
5.3.3

ATP-binding aptamer truncation

I studied T5 truncation of the ATP-binding aptamer to prove T5 could truncate
aptamer structures other than three-way junctions. The ATP aptamer has a stemloop structure with a 4-base pair stabilizing stem and a reportedly folded
conformation even in the absence of target, with limited structural change upon
target binding.208,210,227,228 Indeed, White et al. performed urea denaturation
studies and found that >99.6% of the ATP-aptamer molecules are folded in the
absence of target.48 In contrast, reducing the stem length by 2 base-pairs results
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in the unfolded aptamer confirmation dominating the conformational equilibrium. I
hypothesized that T5 would be inhibited as it approached the presumed binding
site by formation of the ATP-aptamer complex. I modified the previously reported
ATP-binding aptamer by adding 3’ and 5’ overhangs of 5-nt each but otherwise
conserved the same sequence as the original ATP aptamer of Huizenga et al.47
The overhangs have been reported to provide a better binding substrate for T5.113
Thus, the utilized ATP-binding aptamer has a 37-nt long sequence (fig. 46, 37-nt).
As predicted, T5 can truncate 6-nt from the starting aptamer sequence of 37-nt,
yielding a product of 31-nt corresponding to a structure with a 3 base-pair stem
(fig. 46). The concentration of the 31-nt product was plotted over the time course
of the reaction and exhibited a consistent value of >900 nM even after 5 hours
(90% starting concentration). I previously utilized a similar construct with stem
length of 3 base-pairs for detection of adenosine and proved that it underwent
significant target-induced conformational changes (see chapter 4). Thus, T5
truncation of the ATP aptamer can yield an aptamer sequence that possibly
undergoes structure-switching. In the absence of target, two products are
observed over the reaction time course of five hours with lengths of 31-nt and 30nt and corresponding stems of 3 and 2 base-pairs, respectively (fig. 46). After 5
hours only the 30-nt product remains at a concentration of nearly 300 nM. The 30nt structure with the 2 base-pair stem was previously proven to be unfolded in the
conformational equilibrium48, thus it appears from these results that under the
current conditions, digestion of single-stranded DNA by T5 is slow. After 8 hours,
the 30-nt band is consumed in the absence of target but still retained in the
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presence of target (data not shown).

Figure 46. Time course of T5 reaction with ATP-binding aptamer.
Digestion of the aptamer proceeds quickly at first as the 5’ overhang is a good
enzyme substrate, with most of the parent aptamer being processed within 15 min.
In the absence of target, the enzyme can digest most of the structure, yielding a
minor product of 30-nt and concentration of 300 nM. However, in the presence of
target, T5 truncation yields two products of 31- and 30-nt. The major product is 31nt with a corresponding stem of 3 base-pairs and a consistent concentration of
>900 nM over the five-hour reaction window. (right) The band intensity is converted
to concentration by utilizing a control band of known concentration without enzyme
addition. [T5] = 0.1 U/µL, [DNA] = 1 µM, [ATP] = 500 µM at 23°C.
An ATP non-binding sequence was tested to confirm that ATP did not inhibit T5
directly. The non-binding sequence was designed by removal of 8-nt from the 3’
end of the aptamer sequence and 2-nt from the 5’ end and termed ATP.25. The
25-nt sequence is not able to form the binding pocket and it also lacks an essential
binding nucleotide as has been previously described.47 T5 truncation of the ATP.25
yielded the same 20-nt product regardless of the presence or absence of ATP,
proving that ATP does not actively inhibit the enzyme (fig. 47). In contrast, the 37-
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nt ATP binding aptamer inhibited T5 by formation of the ATP-aptamer complex,
yielding the described 31-nt product. A secondary product is observed if the
reaction is left to proceed for longer time, with truncation of 7-nt yielding a product
of 30-nt which correspondingly has a stem of 2 base-pairs. This 30-nt structure
has also been previously reported to retain binding affinity for ATP, thus it appears
T5 can recognize two separate aptamer products that can undergo structureswitching upon target binding.48 The same color-guide is employed to describe the
different reaction products in the presence and absence of ATP as described in
the last section. The T5-guided strategy enables simpler and faster identification
of the structure-switching sequences for stem-loop structures.

Figure 47. T5 inhibition is caused by formation of aptamer-ATP complexes and
not by ATP directly.
A manually truncated non-binding sequence was tested (25-nt) and yielded the
same product of 20-nt regardless of ATP presence or absence. This proves that
ATP does not directly inhibit T5 activity. In contrast, the 37-nt ATP-binding
sequence underwent T5-guided truncation yielding products of 31- and 30-nt. Both
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of these products have been previously shown to retain affinity for ATP. The
column plot represents the band intensity as a measurement of concentration. [T5]
= 0.1 U/µL, [DNA] = 1 µM, [ATP] = 500 µM at 23°C for 340 minutes.
5.3.4

DIS-binding aptamer truncation

To further test the generality of the method, I tested aptamers which specifically
bind the small molecule steroids deoxycorticosterone 21-glucoside (DOG) and
dehydroisoandrosterone 3-sulfate (DIS). Stojanovic et al. previously isolated these
three-way junction aptamers, which display long stabilizing stems and a binding
pocket at the junction of the stems.229 The formation of the junction is required for
binding as it creates a hydrophobic environment by display of aromatic groups of
unstacked nucleotides at the junction, favoring binding of hydrophobic
molecules.58 I utilized T5 to initially truncate the DIS-binding aptamer to yield the
minimum number of base-pairs required for binding of DIS while maximizing the
structure-switching ability of the aptamer. The DIS-binding aptamer structure was
almost fully digested in the absence of binding target with nearly zero bands
present in the lane of this sample (fig. 48, DIS). Incubation with DIS resulted in
nearly complete inhibition of the enzyme with concentrations of the product band
being nearly uniform from the starting concentration, and the major product being
the parent aptamer of 37-nt and a minor product of 36-nt (fig. 48, DIS). Truncation
was not observed with the DIS-binding aptamer, suggesting that all the nucleotides
in the stem are necessary for a high-affinity binding interaction with DIS. This is a
possibility as formation of the binding pocket is required for binding of hydrophobic
molecules.58,229 Indeed, a recently reported and improved DIS-binding aptamer by
Stojanovic et al. has equally long stabilizing stems, suggesting the necessity for all
132

nucleotides for high-affinity binding.230 Thus, it is possible that truncation of these
steroid-binding aptamers is not possible or necessary.

Figure 48. T5-guided truncation of DIS-binding aptamer to identify structureswitching fragments.
The DIS aptamer was digested in the absence of target as expected, with only a
faint product band of 23-nt being observed in the gel image. Addition of DIS
resulted in nearly complete inhibition of T5 yielding products that did not differ in
length when compared to the control sample without enzyme. This might be
possibly because all the nucleotides in the stem are required to stabilize a highaffinity interaction with DIS. [T5] = 0.1 U/µL, [DNA] = 1 µM, [Steroid] = 500 µM at
23°C for 135 minutes.
Direct inhibition of T5 by the steroid DIS was tested by incubating DIS with a control
DNA sequence (an ATP-binding aptamer) that does not bind DIS. The T5 enzyme
digested the control sequence at equal rates in the presence or absence of DIS,
with multiple product bands present and concentration of the parent band below
300 nM after 2 hours, demonstrating that DIS does not inhibit the enzyme directly
(fig. 49a). The enzyme T7 exonuclease was also tested and did not digest the
control sequence in any case (fig. 49a). It is mentioned and included because an
increase in the intensity of the bands in the presence of DIS was present in all
samples and was attributed to overlap between the fluorescence intensity of SYBR
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gold (the fluorescence DNA stain) and DIS (fig. 49c).231 Thus, clearly the enzyme
is not inhibited directly by DIS but rather it is possible that all the nucleotides in the
stem are necessary for target binding under the employed conditions.

Figure 49. Test of T5 inhibition by the steroid molecule DIS.
(a) Gel electrophoresis of reaction products of an ATP-binding aptamer incubated
with DI or DIS at varying times. T5 enzyme digestion of the control DNA was slow
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and it did not vary in the presence or absence of DIS. T7 exonuclease also did not
exhibit digestion of the control aptamer and a mixture of T5 and T7 exhibited similar
response as T5 alone. (b) Time course plots of the band intensity (converted to
concentration) exhibit decreasing band intensity over time, because of enzymatic
hydrolysis and formation of shorter fragments. (c) A difference in the intensity was
observed in the presence of DIS that was attributed to fluorescence overlap
between DIS and the DNA staining dye, SYBR gold. The difference in intensity
was present with both enzymes. This test proves that DIS does not inhibit T5
directly.
5.3.5

T5 activity on DOG-binding aptamer

The DOG aptamer demonstrated the slowest rate of hydrolysis of all the aptamers
tested (data not shown). I hypothesized that addition of a 5’- overhang would aid
in the rate of digestion of the DOG aptamer, as the T5 enzyme can bind 5’
overhangs with higher affinity when compared to blunt double-stranded DNA.232
We modified the DOG aptamer with 5’- overhangs of varying lengths, and a 5’
recessed end to study their effect on enzyme rate. Interestingly, the digestion of
the 5’- overhang was very fast (<5 min.) but it appeared the enzyme would unbind
from the aptamer structure upon cleaving the 5’ overhang, as a major product was
observed at 41-nt regardless of the length of the 5’ overhang. A 5’ overhang of +7nt resulted in a truncation of 8-nt, yielding a 41-nt product and truncation of the +3nt overhang resulted in truncation of 4-nt, yielding the same 41-nt product (fig. 50,
5 mins.). Digestion of the blunted or 5’ recessed aptamer structures was much
slower, necessitating more than five hours to digest in the absence of target (fig.
49, 300 mins). In the absence of target, a faint product is observed at 37-nt,
corresponding to a short 3 base-pair stem which likely signals the stem position
where structure-switching occurs. In the presence of DOG, various products are
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observed although the majority only exhibit minor truncation. Like the DIS aptamer,
the DOG aptamer likely requires all nucleotides in the stem for high-affinity
interaction with the target.

Figure 50. Digestion rate of T5 on 5’ overhangs and double-stranded DNA.
Various aptamers were synthesized with increasingly longer 5’ overhangs to study
the role of binding of the enzyme to 5’ overhangs and 5’ blunt ends. The 5’
overhangs exhibited fast digestion rates, with the extensions of all lengths being
quickly cleaved at the double-stranded junction. Destabilization of the stem by
reducing the number of base pairs resulted in identification of a truncated aptamer
that displayed target-induced inhibition of the enzyme. This sequence presumably
is the minimum number of base pairs that is required for dsDNA formation and
inhibition of T5. [T5] = 0.1 U/µL, [DNA] = 1 µM, [Steroid] = 500 µM at 23°C.
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Additionally, we tested a sequence where the DOG aptamer had a 5’ recessed
end by 3-nt, thus only having a stem of 5 base-pairs. These 5’ recessed structures
also reportedly promote binding of T5 compared to blunt DNA.232 Indeed, T5 can
catalyze the hydrolysis of this structure in the absence of target and addition of
target inhibits the digestion, yielding a truncated sequence with a 3-base pair stem
(fig. 50, DOG.-3). Mfold simulations predict that the 5-base pair aptamer can form
a stable, folded structure that presumably does not undergo significant structureswitching upon target-biding. However, the T5-selected 3 base-pair aptamer is
predicted to form a highly flexible, unfolded sequence which can possibly undergo
target-induced structure-switching.222
A time-course of the reaction between T5 and the 5’ recessed DOG aptamer
variant is shown in figure 51. In the absence of target, T5 can digest the aptamer
structure until it reaches a product of 37-nt yielding a 3 base-pair stem. It is possible
that at this point, the enzyme disengages from the aptamer structure because of a
conformational change in the DNA. After 5 hours, the product at 37-nt is completely
consumed by the enzyme (fig. 51). In the presence of DOG, T5 is inhibited close
to the presumed binding site with a major product of 37-nt being observed even
after 5 hours of reaction with a concentration of >600 nM remaining (fig. 51). The
recessed aptamer can be utilized in combination with T5 to yield a structureswitching DOG aptamer.
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Figure 51. Time course of T5 digestion of DOG.-3 aptamer structure and
enzymatic products visualized using gel electrophoresis.
The enzyme reaction was stopped by mixing of reaction buffer with stop-mix
loading buffer containing high concentrations of EDTA, formamide and urea. The
aptamer is digested at a faster rate in the absence of target, but the enzyme is
significantly inhibited upon addition of DOG because of formation of DOG-aptamer
complex. After 5 hours, the enzyme truncates 2-nt to yield an aptamer of 37-nt and
a corresponding stem of 3 base-pairs (blue line) which appears to be the minimum
number of base-pairs required for binding of target and addition of structureswitching functionality. [T5] = 0.1 U/µL, [DNA] = 1 µM, [Steroid] = 500 µM at 23°C.
5.3.6

Engineering a DOG-binding aptamer for T5 truncation

A DOG-binding aptamer was engineered by changing the stem sequence to
closely match the initial 5 base pairs of the MDPV stem, which does not contain
more than 2 consecutive C-G base pairs and is shown to be readily digested by
T5 (red nucleotides in figure 52). The redesigned sequence can be fully digested
in the absence of target at a much faster rate than the original DOG aptamer (Fig.
52). Increased digestion was also observed in the presence of DOG, with a
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truncated aptamer sequence being identified by the nuclease as a 3-base pair
stem, matching the result using the shorter 5-base pair aptamer (Fig. 52). A smaller
concentration of the 37-nt binding product is observed >300 nM. This might be a
result of incomplete digestion of larger fragments as seen in the gel but could also
be an effect of reduced affinity for DOG because of the nucleotide substitutions in
the stem. It appears that truncation of steroid binding aptamers, which necessitate
highly stable stems, might not be practical or necessary.

Figure 52. T5-guided truncation of redesigned DOG aptamer sequence.
(a) Time course of digestion of redesigned sequence with a 5’ overhang and
several mutated nucleotides that match the MDPV stem. Digestion is faster as
compared to the original sequence and in the absence of target completely
consumes the parent aptamer within 130 minutes. In the presence of target, the
main product has a 3 base-pair stem stabilized by target-binding which inhibits
further enzymatic digestion. The band concentration is plotted as a function of time.
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The blue line in the illustrations represents the product sequence that is identified
in the presence of target and the red line in the absence of target. [T5] = 0.1 U/µL,
[DNA] = 1 µM, [Steroid] = 500 µM at 23°C.
5.4

Conclusion

A T5-guided truncation method is demonstrated to easily and quickly truncate
aptamers to yield aptamer sequences which possibly display structure-switching
functionality and maintain high target affinity. We hypothesized that T5
exonuclease would be inhibited by formation of aptamer-target complexes as is
seen in small molecule footprinting studies utilizing exonuclease III and DNAse
I.110,233 Indeed, formation of aptamer-target complexes inhibit the enzyme activity,
with single or dual products only being observed in the presence of the target as
compared to empty lanes in the absence of target. The method is used to identify
aptamer fragments with structure-switching functionality for targets including
MDPV, DOG and ATP. The enzyme T5 exonuclease demonstrates a unique ability
to recognize the essential aptamer sequence for binding while removing any
unessential nucleotides. The enzyme T7 exonuclease is unable to perform such
function. This strategy will be a key tool -fast, simple, widely available, and low
cost- in development of E-AB sensors which require aptamers with structureswitching functionality.
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CHAPTER 6
Summary and future directions
6.1 Summary
The dissertation describes methods to engineer aptamers to increase analytical
performance, modulate specificity and add functionality with the goal of
overcoming practical limitations of current aptamer-based sensors, especially for
small-molecule detection in real-world sample matrices. In chapter 3, it was
discovered that ATMND could bind to the cocaine aptamer, modulating its
fluorescence when bound (quenched) or free (fluorescent) in solution. Addition of
cocaine would displace the ATMND molecule from the aptamer binding pocket,
resulting in an intense fluorescence signal that could be correlated to cocaine
concentration. Additionally, a cocaine aptamer was engineered with 10-fold higher
affinity for both molecules as compared to previously reported aptamers. The
method was applied to detect cocaine in biological samples such as urine, saliva
and serum. The sensitivity of the method was over 50-fold higher than other
reported aptamer-based methods. The improvement in sensitivity was correlated
to higher affinity for cocaine and sensitive fluorescence signaling from ATMND
displacement.
In chapter 4, an adenosine-specific aptamer was engineered by rational mutation
of the aptamer sequence. A method to quickly screen the mutated sequences was
also introduced, which aided in the identification of the adenosine-specific
aptamer. The aptamer was truncated to introduce structure-switching functionality
and adapted to an electrochemical transducer. The sensor could detect low
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concentrations of adenosine in undiluted serum and exhibited minimal response
to ATP, ADP and AMP. The sensitivity of the sensor was improved by 40-fold when
compared

to

previously

reported

aptamer-sensors

for

undiluted

serum

measurements of adenosine.
In chapter 5, a nuclease-guided method was developed to intelligently truncate
aptamer sequences yielding aptamer fragments

with structure-switching

functionality. As opposed to trial-and-error methods, no prior knowledge of the
binding site is required to yield truncated aptamers. Aptamers with structureswitching functionality can be used directly in a variety of methods that can be
directly applied in complex samples. For example, electrochemical aptamer-based
sensors can be directly utilized in undiluted blood because of the extreme
selectivity of electrochemical detection. The method will allow for development of
E-AB sensors for new aptamers in a simple, fast and low-cost manner.
6.2

Future

Aptamer-based cocaine detection with our fluorescence method suffered from
auto-fluorescence in urine and serum. When the matrix by itself was excited at 358
nm, endogenous molecules in the matrix gave high fluorescence at the monitored
emission wavelength of 405 nm. Thus, detection in complex matrices was limited
to diluted samples which resulted in limited sensitivity. Additionally, the cocaine
aptamer that was engineered displayed strong cross-reactivity with several small
molecules that could be present in biological fluids. To solve both issues, Yu et al.
develop a split-aptamer assay incorporating a fluorophore that is out of the range
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of most of the endogenous fluorescent molecules.234 Thus, this improved method
can detect cocaine in 10% saliva below the recommended cut-off limit established
by the European Union's Driving under the Influence of Drugs, Alcohol and
Medicines program. A similar approach could be taken to identify a fluorophore
outside of the interference range that can bind in the aptamer pocket and be
displaced by the drug target. For example, Sato et al. reported an ATMND-thiazole
orange conjugate that exhibited the same affinity for abasic sites as demonstrated
by ATMND alone but with significantly higher excitation (506 nm) and emission
(530 nm) wavelengths, which are well outside of the auto-fluorescence window of
biological fluids.235 Indeed, it was demonstrated that the conjugate exhibited
nanomolar affinity for cytosine and thymine opposite the abasic site but did not
bind strongly with purine nucleotides. Thus, it is likely that the conjugate could
retain the same affinity for the cocaine aptamer pocket and be utilized as a signal
reporting dye.
We demonstrate the first specific sensor for detection of adenosine in undiluted
serum over similar molecules such as ATP, ADP and AMP. I would like to apply
this sensor technology to measure real patient samples. The test would include a
control healthy population and a diseased population. Generally, adenosine
concentration is much higher in diseased states (>3 µM) vs. healthy individuals (<1
µM).73,75,77 The sensor could be used to calculate the concentration of both
populations and determine a cut-off concentration for disease diagnosis. The
sensor could also be used to profile the activity of adenosine regulating enzymes
to discover new small molecule inhibitors of these enzymes which are often over
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or under-expressed in diseased states. An important limitation of current
measurement techniques for adenosine is the inability to measure adenosine close
to the cell surface, where it is often produced and accumulated. Aptamers have
been previously immobilized onto cell membranes by conjugation with an
intercalating group. For example, Tokunaga et al. previously conjugated the ATPcross reactive aptamer with tocopherol as a direct method to anchor the aptamer
onto cell membranes and monitor ATP release by a fluorescence reporter directly
modified in the aptamer structure.184 A similar approach could be utilized to
measure adenosine in situ, providing much more accurate representation of real
adenosine concentration and production dynamics. To increase the sensitivity, we
can also modify the aptamer to only bind a single adenosine molecule per aptamer
instead of the current two. Zhang et al. recently determined that the classic ATP
aptamer could be engineered to bind only one molecule per aptamer while keeping
the same stem-loop structure, a similar approach could be taken with our new
adenosine-specific aptamer.197 This would immediately increase the sensitivity by
at least two-fold.
Aptamer truncation was also demonstrated with T5 exonuclease as a key tool to
develop structure-switching aptamers which have been widely used in
electrochemical-based sensors. However, the structure-switching functionality of
the aptamers was not directly measured. Thus, experiments such as circular
dichroism could be performed to measure the changes in the truncated aptamer
structure before and after target binding and further comparing the results to fully
folded aptamers. Urea denaturation studies could also be attempted to observe
144

whether the truncated sequences are fully denatured in the absence of target.
Additionally, isothermal titration calorimetry must be employed to determine the
binding affinity and thermodynamics of binding of the truncated sequences as
compared to the original parent aptamer. Finally, the identified structure-switching
aptamers must be functionalized with an electroactive group and utilized in E-AB
sensors to determine their analytical characteristics and functionality in complex
samples.
The T5 exonuclease method can also be used independent of aptamer-sensors to
yield truncated aptamer sequences that can provide higher specificity than fully
folded aptamers. We previously demonstrated that the truncated aptamer for
cocaine does not bind ATMND favorably. Several non-specific binders do not
actively induce structure-switching; thus, specificity is improved upon truncation.
The method could also potentially be used for development of a SELEX process
as the enzyme can differentiate between target-binding and non-binding
sequences, as T5 will fully digest the non-binding sequences while leaving targetbinding aptamers behind.
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